

5-7-2011

A Descriptive Review of Balamuthia and Non-Keratitis Acanthamoeba Cases in the United States, 1955-2009

Melanie A. Moser

Georgia State University, mmoser1@student.gsu.edu

Follow this and additional works at: http://digitalarchive.gsu.edu/iph_theses

Recommended Citation

Moser, Melanie A., "A Descriptive Review of Balamuthia and Non-Keratitis Acanthamoeba Cases in the United States, 1955-2009" (2011). *Public Health Theses*. Paper 162.

This Thesis is brought to you for free and open access by the Institute of Public Health at Digital Archive @ GSU. It has been accepted for inclusion in Public Health Theses by an authorized administrator of Digital Archive @ GSU. For more information, please contact digitalarchive@gsu.edu.

ABSTRACT

MELANIE A. MOSER

A Descriptive Review of *Balamuthia* and Non-Keratitis *Acanthamoeba* Cases in the United States, 1955-2009

(Under the direction of Richard Rothenberg, Professor)

Free-living amoebae are ubiquitous in the environment and occasionally invade and parasitize host tissues causing illness in humans. Despite possibly frequent exposure to these organisms, infection is rare and why some people, healthy or not, end up with illness and others do not is still unclear. Human infections are rare; when illness does occur, it is often fatal. Only two papers have examined data from the literature and cases reported to the Centers for Disease Control and Prevention, and both were published over twenty years ago. The purpose of this study is to better document the epidemiology of *Balamuthia* and non-keratitis *Acanthamoeba*, give insight into trends of these infections over time, and contribute to the scientific and medical community by producing the only comprehensive review of all *Balamuthia* and non-keratitis *Acanthamoeba* cases in the United States from 1955 through 2009. This study also examines cases that have survived in an attempt to determine if there is evidence for the effectiveness of a particular treatment regimen. Only a small number of patients have survived these infections, so any evidence for a successful course of treatment could be crucial for future cases.

INDEX WORDS: free-living amoebae, *Balamuthia mandrillaris*, *Acanthamoeba* spp., non-keratitis *Acanthamoeba*

A DESCRIPTIVE REVIEW OF *BALAMUTHIA* AND NON-KERATITIS
ACANTHAMOEBA CASES IN THE UNITED STATES, 1955-2009

by

MELANIE A. MOSER
B.S. FROSTBURG STATE UNIVERSITY

A Thesis Submitted to the Graduate Faculty
of Georgia State University in Partial Fulfillment
of the
Requirements for the Degree

MASTER OF PUBLIC HEALTH

ATLANTA, GEORGIA
2011

APPROVAL PAGE

A DESCRIPTIVE REVIEW OF *BALAMUTHIA* AND NON-KERATITIS
ACANTHAMOEBA CASES IN THE UNITED STATES, 1955-2009

by

MELANIE A. MOSER

Approved:

Richard Rothenberg, MD, MPH, FACP

Committee Chair

Sharon Roy, MD, MPH

Committee Member

April 13, 2011

Date

DEDICATION PAGE

This thesis is dedicated to all those who have suffered from and succumb to free-living ameba infections. May this work, in some small way, help to illuminate what is known and what further work needs to be done to ensure others have improved outcomes.

ACKNOWLEDGEMENTS

I would like to thank Dr. Govinda Visvesvara, head of the Free-Living Ameba Laboratory at the Centers for Disease Control and Prevention, and his lab assistant, Mrs. Rama Sriram. Without the diagnostic work performed by the FLA Lab, efforts to investigate cases sent to the lab, maintenance of historical files, and Dr. Visvesvara's long and precise memory, this thesis could not have been undertaken. Dr. Visvesvara has worked tirelessly for over 30 years to improve diagnosis of free-living ameba infections and contribute to a greater understanding of the organisms; it was a sincere pleasure and honor to have his assistance on this project. I would also like to thank the Waterborne Disease Prevention Branch's (WDPB) Dr. Sharon Roy and Mr. Jonathan Yoder for their encouragement of this project and their willingness to serve as thesis committee member and practicum preceptor respectively. Dr. Roy was exceedingly patient and helpful in reviewing this document multiple times. Her suggestions on how to examine the data were crucial to this work. The practicum experience was foundational to the consolidation of some of the data explored in this thesis and proved to be an invaluable learning experience in how informal surveillance systems are developed and implemented.

I would also like to thank faculty at the Institute of Public Health at Georgia State University. Thanks to Dr. Richard Rothenberg for teaching epidemiology courses in such an engaging way, for always reminding students to look behind the numbers and ask questions, and for directing this thesis project. Also thanks to Dr. Sheryl Strasser for her encouragement in pursuing this thesis topic during her Research Methods class. I wasn't

convinced a descriptive study was important enough to undertake, but our after-class conversations made me a believer. Although they were not involved in the thesis process, both Professor Russell Toal and Dr. Frances McCarty are exceptional faculty. Professor Toal was an inspiration in my first semester of graduate studies, showing real commitment to public health and social justice. Dr. McCarty was a wealth of patience and practicality in the biostatistics courses I had with her. Although I'll never be a statistician, she is the proof of why they are so needed in public health.

Lastly, I would like to thank my husband, Greg McNamara, for his encouragement and support in my decision to return to school to pursue a graduate degree. Public health is my passion and I thank him for his patience and willingness to listen as I went through this course of study and for his keen eyes in reviewing this document for errors.

AUTHOR'S STATEMENT

In presenting this thesis as a partial fulfillment of the requirements for a Master of Public Health from Georgia State University, I agree that the Library of the University shall make it available for inspection and circulation in accordance with its regulations governing materials of this type. I agree that permission to quote from, to copy from, or to publish this thesis may be granted by the author or, in her absence, by the professor under whose direction it was written, or in his absence, by the Associate Dean, College of Health and Human Sciences. Such quoting, copying, or publishing must be solely for scholarly purposes and will not involve potential financial gain. It is understood that any copying from or publication of this dissertation which involves potential financial gain will not be allowed without written permission of the author.

Melanie A. Moser

Signature of Author

NOTICE TO BORROWERS

All theses deposited in the Georgia State University Library must be used in accordance with the stipulations prescribed by the author in the preceding statement.

The author of this thesis is:

Student's Name: Melanie A. Moser

Street Address: 216 Leigh's Trace

City, State, and Zip Code: McDonough, GA 30253

The Chair of the committee for this thesis is:

Professor's Name: Richard Rothenberg, MD, MPH, FACP

Department: Institute of Public Health

College: Health and Human Sciences

Georgia State University
P.O. Box 4018
Atlanta, Georgia 30302-4018

Users of this thesis who not regularly enrolled as students at Georgia State University are required to attest acceptance of the preceding stipulation by signing below. Libraries borrowing this thesis for the use of their patrons are required to see that each user records here the information requested.

NAME OF USER	ADDRESS	DATE	TYPE OF USE (EXAMINATION ONLY OR COPYING)

Melanie Ann Moser
216 Leigh's Trace
McDonough, GA 30253
melaniemoser@bellsouth.net

Education:

1989 B.S., History, Frostburg State University, Frostburg, MD

Professional Experience:

2010-present Public Health Analyst, Centers for Disease Control and Prevention (CDC), Division of Parasitic Diseases and Malaria, Office of the Director, Atlanta, GA

2010 Public Health Analyst, CDC, Division of Enteric, Foodborne, and Waterborne Diseases, Waterborne Disease Prevention Branch, Office of the Director, Atlanta, GA

2007-2010 Public Health Analyst, CDC, Division of Parasitic Diseases, Parasitic Diseases Branch, Office of the Director, Atlanta, GA

2001-2007 Health Communication Specialist*, Atlanta Research and Education Foundation, Decatur, GA; *As Guest Researcher at CDC, Division of Parasitic Diseases, Parasitic Diseases Branch, DPDx

2000-2001 Research Analyst, Physician Workforce Resource Center, Mercer University, Macon, GA

1999-2000 Research Assistant, Office for Social Environment and Health Research, West Virginia University (WVU), Morgantown, WV

1996-1999 Program Assistant, Office for Health Services Research, WVU, Morgantown, WV

Presentations:

The DPDx Project, Where Parasitology and Technology Meet: Telediagnosis and Internet-based tools to enhance the diagnosis of parasitic diseases. Centers for Disease Control and Prevention, Science Ambassador's supplemental lecture. July 25, 2007.

Usefulness of Telediagnosis in Confirmatory Laboratory Diagnosis of Cases of Parasitic Infections. American Society of Tropical Medicine and Hygiene. Atlanta, GA. November 11, 2006.

DPDx: What is it and what can it do for me? A teleconference for U.S. public health departments. Sponsored by the National Laboratory Training Network. October 19, 2005.

Encountering Food and Waterborne Intestinal Parasites. Sponsored by the National Laboratory Training Network and the Centers for Disease Control and Prevention. Various training workshops including: Albuquerque, NM, August 8-10, 2005; St. Thomas, Virgin Islands. June 27-29, 2005; Warwick, RI. September 11-12, 2003; Lionville, PA. September 8-9, 2003; Reno, NV. September 16, 2002.

Bloodborne Pathogens: Plasmodium & Babesia Workshop. Sponsored by the National Laboratory Training Network and the Centers for Disease Control and Prevention. Various training workshops including: Albuquerque, NM, August 8-10, 2005; St. Thomas, Virgin Islands, June 27-29, 2005; Baltimore, MD, September 13-14, 2004; Durham, NH, August 24-25, 2004.

Telediagnosis and Internet-based tools to enhance the diagnosis of parasitic diseases. [poster] American Society of Tropical Medicine and Hygiene. Miami, FL. November 11, 2004.

DPDx: Laboratory Identification of Parasites of Public Health Concern. Public Health Education and Promotion Network Award Ceremony, Atlanta, GA. October 22, 2004.

Food Safety Training & Education. Sponsored by the Georgia Association for Food Protection. Atlanta, GA. February 11, 2003.

Publications:

Moser, M., Bartlett, M., and A. da Silva. "DPDx project receives PHEP-Net's Award of Excellence in Public Health Training." *NCID FOCUS*. Winter-Spring 2005. 14(1);9.

Shah, S., et al. "Malaria Surveillance --- United States, 2002," *Morbidity and Mortality Weekly Report, Surveillance Summaries*. April 30, 2004. 53(SS01);21-34. Available from: URL: <http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5301a3.htm> (Provided illustrations only)

da Silva, A. and N. Pieniazek. "Latest Advances and Trends in PCR-Based Diagnostic Methods." In *Textbook-Atlas of Intestinal Infections in AIDS*. Ed. Daniele Dionisio. Springer. 2003. (Provided illustrations only)

Moser, M. and A. da Silva. "Featured Collection: DPDx." *D-Lib Magazine*. June 2002. 8(6). Available from: URL: <http://www.dlib.org/dlib/june02/06featured-collection.html>

Lubman, A. and M. Moser. *West Virginia State Census Data Center Newsletter*. Morgantown Printing and Binding: Morgantown, WV, Fall 1996-Fall 1997.

Bell, R., et al. "The Burden of Diabetes in Appalachia." *Poster session presented to the Centers for Disease Control, Division of Diabetes Translation*. Biomedical

Communications: Morgantown, WV, August 1999. (Provided maps only)

Awards and Honors:

March 2009	National Center for Zoonotic, Vectorborne, and Enteric Diseases Award of Excellence for Communication Services
April 2008	Award of Excellence in Public Health – <i>Acanthamoeba</i> keratitis Epi & Lab Research Team
October 2004	Award for Excellence in Public Health Training – DPDx Team

Skills and Qualifications:

- SAS, SPSS
- Microsoft Access
- ArcView GIS
- Adobe Dreamweaver, Fireworks, Flash, Photoshop, Illustrator, and Acrobat

TABLE OF CONTENTS

	Page
DEDICATION.....	iii
ACKNOWLEDGEMENTS.....	iv
LIST OF TABLES.....	vi
LIST OF FIGURES.....	viii
CHAPTERS	
I. INTRODUCTION.....	1
Background.....	1
Purpose of the Study.....	4
Research questions.....	5
II. REVIEW OF THE LITERATURE.....	7
Disseminated infections.....	7
Granulomatous amebic encephalitis (GAE).....	11
Cutaneous acanthamoebiasis.....	14
<i>Acanthamoeba</i> rhinosinusitis.....	15
<i>Acanthamoeba</i> osteomyelitis.....	15
Survivors: <i>Acanthamoeba</i>	16
Survivors: <i>Balamuthia</i>	20
Ethnicity.....	23
III. METHODS AND PROCEDURES.....	25
IV. RESULTS.....	29
Demographics: Research Question 1.....	30
Presenting Symptoms: Research Question 2.....	34
Treatment: Research Question 3.....	44
Duration of Illness: Research Question 4.....	46
Further Data Analysis.....	46
V. DISCUSSION AND CONCLUSION.....	52
REFERENCES.....	59

APPENDICES

A.	DETAILED TABLES OF ALL PUBLISHED NON-KERATITIS <i>ACANTHAMOEBA AND BALAMUTHIA CASES</i>	66
B.	CASE REPORT FORM.....	74
C.	EPIDEMIC CURVES FOR NON-KERATITIS..... <i>ACANTHAMOEBA AND BALAMUTHIA CASES</i>	85
D.	TREATMENT REGIMENS FOR SUVIVORS.....	89

LIST OF TABLES

	Page
Table 1: Summary of Demographic for Non-Keratitis <i>Acanthamoeba</i> spp. and... and <i>Balamuthia mandrillaris</i> Cases	33
Table 2: Top Ten Presenting Symptoms of Patients Later Diagnosed with..... Non-Keratitis <i>Acanthamoeba</i> spp. Infection	34
Table 3: Top Ten Presenting Symptoms of Patients Later Diagnosed with..... <i>Balamuthia mandrillaris</i> Infection	34
Table 4: Presenting General Symptoms for Cases of Non-Keratitis..... <i>Acanthamoeba</i> spp. Infection by Disease Manifestation	35
Table 5: Presenting Visual Symptoms for Cases of Non-Keratitis..... <i>Acanthamoeba</i> .spp. Infection by Disease Manifestation	37
Table 6: Presenting Neurologic Symptoms for Cases of Non-Keratitis..... <i>Acanthamoeba</i> spp. Infection by Disease Manifestation	37
Table 7: Presenting Skin Lesions for Cases of Non-Keratitis <i>Acanthamoeba</i> spp. Infection by Disease Manifestation	38
Table 8: Presenting General Symptoms for Cases of <i>B. mandrillaris</i> Infection..... by Disease Manifestation	39
Table 9: Presenting Visual Symptoms for Cases of <i>B. mandrillaris</i> Infection..... by Disease Manifestation	39
Table 10: Presenting Neurologic Symptoms for Cases of <i>B. mandrillaris</i> Infection by Disease Manifestation	40
Table 11: Presenting Skin Lesions for Cases of <i>B. mandrillaris</i> Infection..... by Disease Manifestation	41
Table 12: Comparison of Top Five Presenting Symptoms for Disseminated..... <i>Acanthamoeba</i> and <i>Balamuthia</i> Disease	41
Table 13: Comparison of Top Five Presenting Symptoms for <i>Acanthamoeba</i> and <i>Balamuthia</i> GAE	43

Table 14: Drugs in Common for Non-Keratitis <i>Acanthamoeba</i> Survivors.....	45
Compared to Non-Survivors	
Table 15: Drugs in Common for <i>Balamuthia</i> Survivors Compared to Non-.....	45
Survivors	
Table 16: Past Medical Conditions That May Be Predisposing Factors for.....	48
Non-Keratitis <i>Acanthamoeba</i> spp. Infection	
Table 17: Positive Non-Keratitis <i>Acanthamoeba</i> Patients Reporting Another.....	49
Immunocompromising Condition by HIV Status	
Table 18: Past Medical Conditions That May Be Predisposing Factors for.....	50
<i>Balamuthia mandrillaris</i> Infection	
Table 19: Final Diagnosis of Cases of Non-Keratitis <i>Acanthamoeba</i> spp	50
. Infection	
Table 20: Final Diagnosis of Cases of <i>Balamuthia mandrillaris</i> Infection.....	51

LIST OF FIGURES

	Page
Figure 1: Epidemic Curve for Cases of Non-Keratitits <i>Acanthamoeba</i> spp.— United States, 1955-2009	29
Figure 2: Epidemic Curve for Cases of <i>Balamuthia mandrillaris</i> —United..... States,1974-2009	30
Figure 3: Epidemic Curve by Age for Cases of Non-Keratitits <i>Acanthamoeba</i> spp.—United States, 1955-2009	31
Figure 4: Geographic Distribution of Non-Keratitits <i>Acanthamoeba</i> spp..... Cases by State of Treatment	31
Figure 5: Epidemic Curve by Age for Cases of <i>Balamuthia mandrillaris</i> —..... United States, 1974-2009	32
Figure 6: Geographic Distribution of <i>Balamuthia mandrillaris</i> Cases by..... State of Treatment	33

CHAPTER I: INTRODUCTION

Background

Free-living amoebae are ubiquitous in the environment and occasionally invade and parasitize host tissues causing illness in humans.^{1,2} Although human infections are rare, when illness does occur, it is often fatal. There are four genera of free-living amoebae known to infect humans.² *Naegleria fowleri*, which can cause primary amoebic meningoencephalitis (PAM), is described in the media as the “brain-eating amoeba”^{3,4} and news reports of infections with this organism have likely raised awareness of free-living amoebae. Other free-living amoebae, such as *Balamuthia mandrillaris* and *Acanthamoeba* spp. can cause granulomatous amoebic encephalitis (GAE), an infection of the central nervous system. Although there is only one species of *Balamuthia* known to infect humans, *B. mandrillaris*, there are multiple species of *Acanthamoeba*, at least eight, that can cause human infection. Acanthamoebiasis and balamuthiasis can manifest as disseminated infections throughout the body or localized in an area of the body, often affecting the brain, skin, and/or sinuses, as well as other organs such as the lungs, liver, kidneys or lymph nodes, either independently or in combination. *Acanthamoeba* spp. can also cause keratitis, which may threaten an infected person’s vision by causing ulceration of the cornea, diminished sight, or even blindness. *Sappinia diploidea* also has been identified as the cause of one reported case of encephalitis.¹

Naegleria fowleri has been isolated from warm freshwater, geothermal waters, soil, sewage, and unchlorinated or minimally chlorinated swimming pools.^{5,6} Likewise *Acanthamoeba* spp. have been found in soil, sewage, swimming pools, and freshwater but

have also been identified in hot tubs, sea or brackish water, heating/ventilating/air conditioning (HVAC) units, dialysis machines, contact lens solutions, and intra-uterine devices (IUDs).⁶ *Balamuthia mandrillaris* is found in soil.^{7,8} *Balamuthia* might also be present in freshwater; there have been reports of *Balamuthia* GAE in dogs that swam in ponds but there have been no reported human cases where the only potential exposure was swimming.^{9,10} Because these amoebae naturally inhabit so many locations, it is likely that humans are frequently exposed to them. Immunologic studies of *N. fowleri*, *Acanthamoeba* spp., and *B. mandrillaris* have shown that some humans have antibodies to them.¹ Two serologic studies carried out in the United States showed that persons who had extensive contact with freshwater lakes had antibody response to *N. fowleri*.¹¹ Antibodies to *B. mandrillaris* and *Acanthamoeba* spp. have been demonstrated in healthy as well as hospitalized persons.¹ Despite possibly frequent exposure, infection is rare and why some people, healthy or not, end up with illness and others do not is still unclear.

Culbertson was the first to suggest that free-living amoebae could possibly cause infection in humans and showed pathogenicity using animal models.^{2,12} Butt described the first U.S. cases of free-living amoeba infection, PAM caused by *N. fowleri*, in 1966.¹³ Less than ten years later in 1972, Jager and Stamm reported the first human case of *Acanthamoeba* disease, which occurred in the U.S, although it was another eight years before it was definitively recognized that *Acanthamoeba* was the causal agent not *Hartmannella* as was supposed in the original case report.^{14,15} Eventually several reports preceding the 1966 first report of free living amoeba infection were retrospectively identified as cases of *Acanthamoeba* spp. as understanding of the organisms increased.² Recognition that *Balamuthia* (referred to as leptomyxid amoeba at the time) was also a

cause of human infections came in 1990 with a report of cases of GAE due to leptomaxid; the first U.S. was later retrospectively identified as occurring in 1978.¹⁶

N. fowleri primarily affects immunocompetent children and young adults and without treatment has a rapid clinical course resulting in death within 1 to 2 weeks after exposure.¹ In 1980, Martinez was the first to note that *Acanthamoeba* is an opportunistic infection affecting persons with chronic illness.¹⁷ This characterization seems to remain true as most reviews consider it to be an infection that typically affects immunocompromised persons.^{1,2,17} It is thought that there is a subacute phase of infection and the timeframe has not been well characterized, but once the acute phase commences, the infection can be fatal within weeks. *B. mandrillaris* has been reported to affect both immunocompromised and healthy individuals.¹ Of note, recent reports of *Balamuthia* infection via organ transplantation raise concerns for the organ procurement community.^{18,19} The clinical course of balamuthiasis is thought to be the same as that of acanthamoebiasis. Like *Acanthamoeba*, *Balamuthia* can also infect tissues outside the central nervous system.¹ Unlike with *Acanthamoeba* and *Naegleria*, it has been reported that being of Hispanic ethnicity may be a risk factor for *B. mandrillaris* infection.^{1,20}

There are subtle differences in the routes of human infection among the free-living amoebae. *N. fowleri* enter the nasal cavity, attach to the nasal mucosa, cross the nasal-brain (cribriform) barrier, and invade the brain. This invasion results in hemorrhagic necrosis as the amoebae lyse or ingest red blood cells and/or digest or destroy brain tissue through secretions in their food cups.^{1,11} *Acanthamoeba* spp. is thought to invade the body via the nasopharyngeal route, breaks in the skin, or by inhalation of cysts. The organism also produces food cups and secretes enzymes that may aid its

spread throughout the body. *Balamuthia* is thought to have some similarity to *Acanthamoeba* in its route of infection and its possession of particular enzymes that aid in its invasion process, but little is known about its pathogenesis.¹

Meningoencephalitis is the swelling of the brain and its membranes. Butt first introduced the concept of primary amebic infection to differentiate between *Entamoeba histolytica*'s secondary infection of the brain (via the bloodstream) and *Naegleria*'s direct infection.¹¹ Later, Martinez differentiated between the manifestations of free-living amebae infections caused by *Acanthamoeba* and *Naegleria*, particularly the changes occurring in the tissues of the brain, giving further distinguishing differences between PAM and GAE. PAM was characterized as "severe acute necrotizing and hemorrhagic meningoencephalitis involving mainly the base of frontal lobes and posterior fossa" (p. 570) with lesions located on the surface of the brainstem, cerebellum, and cerebral hemispheres.¹⁷ GAE's characteristics included: leptomeninges with moderate amount of purulent exudate over most affected cortical areas, moderate to severe edema in the cerebral hemisphere, and "foci of encephalomalacic worsening associated with small areas of hemorrhagic necrosis in occipital, parietal, temporal, or (less often) frontal lobes" (p. 569). GAE lesions vary in their location and composition.¹⁷

Purpose of the Study

There have been many case reports of free-living ameba infections in the United States, publications on diagnostic techniques and immunology, and reviews of the organisms; but there is still much to learn about the epidemiology and clinical course of these infections. A few case reports and reviews have attempted to summarize a limited number of published cases of acanthamoebiasis and balamuthiasis,^{21,22} or have examined

specific aspects of these infections, such as case reports of *Acanthamoeba* GAE or *Acanthamoeba* rhinosinusitis among AIDS patients.^{23,24} Only two papers have examined data from the literature and cases reported to CDC, and both were published over twenty years ago.^{6,16} A recently published article concerning the epidemiology of primary amebic meningoencephalitis caused by *Naegleria fowleri* in the United States gives a comprehensive review of cases using multiple sources of information such as the Centers for Disease Control and Prevention's (CDC) Free-Living Ameba (FLA) Laboratory case registry and Waterborne Disease and Outbreak Surveillance System, as well as the National Vital Statistics System, published case reports, and media reports.²⁵ The descriptive analysis presented within this thesis is modeled on the methodology of the PAM epidemiology paper and will examine *Balamuthia* and non-keratitis *Acanthamoeba* cases in the United States from 1955 to 2009 by accessing the FLA Laboratory case registry and published case and media reports.

The purpose of this study is to better document the epidemiology of *Balamuthia* and non-keratitis *Acanthamoeba*, give insight into trends of these infections over time, and contribute to the scientific and medical community by producing the only comprehensive review of all known U.S. cases of *Balamuthia* and non-keratitis *Acanthamoeba* through 2009. Along with bringing about a better understanding of the characteristics of these cases, this study will also examine cases that have survived and attempt to determine if there is any evidence for a given treatment regimen as being particularly effective. Only a small number of patients have survived these infections, and any evidence for a successful course of treatment could be crucial for future cases.

Research questions

1. Are there any demographic characteristics that indicate commonality between cases and suggest that persons of a particular ethnicity or race are more predisposed to infection? In particular, does *Balamuthia* disproportionately affect persons of Hispanic ethnicity as suggested in the literature?
2. Are there any presenting symptoms that are particular to acanthamoebiasis and balamuthiasis that would assist clinicians in early identification of free-living ameba infection?
3. Are there any commonalities in the treatment regimen of those who survived?
4. What is the time from onset of symptoms to death?

CHAPTER II: REVIEW OF THE LITERATURE

There have been more than 60 case reviews or reports citing cases of non-keratitis *Acanthamoeba* disease and over 40 cases of *Balamuthia* disease in the United States published between 1960 and 2009. The first case report of *Acanthamoeba* disease was published in 1960, five years after the actual case occurred, and was reported as a granuloma of the brain, likely due *Endolimax williamsi*.²⁶ This same case was cited in several subsequent publications as *Acanthamoeba* granulomatous amebic encephalitis (GAE) upon retrospective review.^{6,17,21,27} The first case report of *Balamuthia* disease was published in 1974; although *Balamuthia* was not recognized as the causal agent at the time, it was reported as a case of free-living amebic meningoencephalitis that was not due to *Naegleria* or *Acanthamoeba*.²⁸ The case was cited as *Balamuthia* GAE in subsequent publications.^{6,17,27} Appendix A has detailed tables of all published *Acanthamoeba* and *Balamuthia* case reports.

Disseminated infections

A review of the literature reveals *Acanthamoeba* disease manifests itself in various ways (disseminated, GAE, cutaneous, rhinosinusitis, osteomyelitis) as does *Balamuthia* (disseminated and GAE). But unlike *Acanthamoeba*, disseminated balamuthiasis always involves the brain. Disseminated *Acanthamoeba* disease was the most frequently reported manifestation of acanthamoebiasis in the United States, with 29 cases published in the literature. [See Appendix A, Table 1 for all disseminated acanthamoebiasis case references.] The majority (n=19) of reported disseminated

infections were in patients who had human immunodeficiency virus (HIV) or who had acquired immune deficiency syndrome (AIDS). [See cases 5-11, 13-19, 21, 22, 24, 25, and 28.] While HIV/AIDS was the predominant cause for immunosuppression among case patients with disseminated acanthamoebiasis reported in the literature, it was followed by those with a previous medical history of organ transplantation and immunosuppressive drug therapy (n=4; cases 4, 23, 27, and 29) and bone marrow transplants due to cancer (n=3; cases 12, 20, 26). One case was reported as having lupus and two case reports cited no known predisposing health factors (cases 3, 1, and 2 respectively).

The most common form of disseminated *Acanthamoeba* disease was a combination of skin and sinus infection (n=10; cases 5, 8, 11, 13-15, 21, 22, 24, 28), followed by cases with a combination of GAE and cutaneous infection (n=3; cases 6, 9, 20). There were two reports of patients with GAE, cutaneous, and lung disease (cases 3, 29), two reports of patients with GAE and lung disease (cases 10, 26), and two cases with cutaneous infection and osteomyelitis (cases 17, 27). The other disseminated manifestations varied greatly among the patients. Those cases that included GAE and other manifestations were: GAE, cutaneous, and sinus (n=1; case 19); GAE and keratitis (n=1; case 1); GAE, lungs, and adrenals (n=1; case 12); GAE, cutaneous, and pulmonary hyaline membrane (n=1; case 4); and GAE, cutaneous, sinus, lymph nodes, thyroid, and adrenals (n=1; case 2). Other disseminated cases included: cutaneous, lungs, and keratitis (n=1; case 7); cutaneous, lungs, heart, kidney, spleen, and lymph nodes (n=1; case 16); cutaneous, sinus, and osteomyelitis (n=1; case 18); cutaneous, liver, and bronchoalveolar lavage (n=1; case 23). One case reported sinus and lung involvement (case 25).

The majority of the disseminated acanthamoebiasis cases were in adult males (n=18; cases 4-10, 13-15, 18, 19, 21, 22, 24-26, 29), and all children (<18 years of age) reported to have disseminated acanthamoebiasis were boys (n=4; cases 1, 11, 16, 17). Seven females were reported with disseminated disease (cases 2, 3, 12, 20, 23, 27, 28). Three reports noted that the patients were of Hispanic ethnicity (cases 2, 11, and 14) although two additional cases were perhaps of Hispanic ethnicity (cases 6 and 28), being described as Mexican American and Nicaraguan, respectively. However, the other 26 case reports failed to describe ethnicity, so an assessment of proportion of cases by ethnicity cannot be made. Only two reports included information about possible environmental exposures and they were both water exposures, one from fishing on a freshwater lake (case 29) and one from wading in drainage ditches (case 1). When timeframes were able to be determined, the number of days between suspected onset of symptoms and death ranged from 8 to 765 days (cases 1-3, 5, 6, 8, 10-13, 16, 19-23, 25, 26, 29). Three cases resolved their infections and did not die (cases 17, 23, 24) and eight did not have adequate information on the symptom onset/death timeframe to determine outcome status (cases 4, 7, 9, 14, 15, 18, 27, 28). The number of days between hospitalization and death ranged from 2 to 120 days (cases 1-7, 9, 10, 14, 15, 18, 25, 26, 27, 28). Twelve cases did not have adequate information on the hospitalization/death timeframe (cases 7, 8, 11, 12, 13, 16, 17, 19, 20, 21, 22, 28). Prognosis for those diagnosed with disseminated disease was poor, with 25 cases having died either from *Acanthamoeba* infection or from other complications (cases 1-16, 18-21, 25-29). In one case, it is unknown whether the patient survived (cases 22). Three cases were still living at the time of the published report, with follow-ups of one month (case 24) and 12

months (case 23). The third report did not give a timeframe but mentioned the patient was still being maintained on therapy (case 17).

In contrast, only seven cases of disseminated *Balamuthia* have been reported. [See Appendix A, Table 2 for all disseminated balamuthiasis case references.] The information concerning potential health-related predisposing factors for these cases was limited and varied, including a history of alcohol or drug abuse (n=3; cases 1, 2, 6), otitis media (n=1, case 5), a history of a farm accident resulting in a contaminated wound and subsequent limb amputation (n=1, case 3), and ankylosing spondylitis (n=1; case 4). One case-patient had a history of coronary artery disease (case 7), but it is unclear whether this medical condition was significant or not given that *Balamuthia* organisms were found in the CSF and skin but nowhere else. Unlike acanthamoebiasis, all the manifestations of disseminated balamuthiasis included GAE. The majority of cases were GAE and cutaneous infections (n=4; cases 3, 4, 6, 7), and the rest were GAE with infection of another organ outside the brain (n=3; cases 1, 2, 5).

As with disseminated acanthamoebiasis, the majority of cases of disseminated balamuthiasis were in adult males (n=6; cases 1-4, 6, 7). Only one child was reported to have this manifestation of illness and this case was female (case 5); this same case was reported as being of Hispanic ethnicity and having a travel history to Mexico. Ethnicity was reported in one other case (case 6, Hispanic), but the remaining 5 case-patients with disseminated balamuthiasis had no ethnicity reported so no pattern can be determined from these data. Environmental exposure history was limited with only two reports providing information: both mentioned potential soil exposures (case 3, 4). When timeframes could be determined, the number of days between suspected onset of

symptoms and death ranged from 24 to 568 days (cases 1-3, 5-7). One case-patient resolved his infection and did not die, but the case report did not provide adequate information to determine the time period between symptom onset and resolution (case 4). The number of days between hospitalization and death ranged from 13 to 77 days (cases 1-3, 5-7). Clinical outcomes for disseminated *Balamuthia* disease were also poor, with six of the case-patients dying (cases 1-3, 5-7) and one reported survivor (case 4). This patient was followed for more than five years and seemed to have recovered from his infection.

Granulomatous amebic encephalitis (GAE)

There are 21 published reports of granulomatous amebic encephalitis caused by *Acanthamoeba* spp. from 1955 to 2009. [See Appendix A, Table 3 for all *Acanthamoeba* GAE case references.] Similar to the disseminated form of acanthamoebiasis, the most common predisposing condition among infected patients was HIV/AIDS (n=4, cases 10, 11, 14, 20), and an equal number of patients with GAE had a history of substance and alcohol abuse (n=4; cases 2, 3, 15, 21). Other potential predisposing health conditions included: cancer (n=2) with long-term immunosuppression (case 5) and with a stem cell transplant (case 16); organ transplantation (n=2) with immunosuppressive therapy (cases 17) and with diabetes (case 19); lupus (n=2; case 18), where one case-patient was also dependent on drugs and alcohol and counted above as having history of substance abuse (case 21); mixed connective tissue disorder (n=1; case 9); and pneumonitis (n=1, case 6). One case-patient (case 4) had a stroke, but it is unknown if this may be a predisposing condition. Of the 21 reports, five had either unknown or unpublished health conditions (cases 1, 7, 8, 12, 13) that may have made them more susceptible to infection.

The majority of cases of *Acanthamoeba* GAE were adult males (n=13; cases 2-5, 10-15, 17, 19, 20). Only three cases were in children under the age of 18, and all of them were female (cases 1, 7, 8). There were five adult females with *Acanthamoeba* GAE (cases 6, 9, 16, 18, 21). No case reports noted patients of Hispanic ethnicity. Two reports noted that case-patients had water exposures; one case-patient was exposed to water that had accumulated in a basement (case 3), but the source of the water was not specified, and the other case-patient frequently used swimming pools for therapy after a cerebrovascular accident (case 4). A third case-patient, a male, had multiple exposures, including a potential occupational exposure (general contractor) and exposures to water and soil. He played volleyball on sand courts and also gardened as a hobby. He also enjoyed fishing and was on a trip approximately one month prior to his illness onset, although he denied direct water contact (case 19). The remaining 18 case reports did not comment on potential environmental exposures. When timeframes could be determined, the number of days between suspected onset of symptoms and death ranged from 8 to 252 days (cases 1, 5, 6, 9, 10, 11, 14-21). Seven did not have adequate information on the symptom onset/death timeframe (cases 2-4, 7, 8, 12, 13). The number of days between hospitalization and death ranged anywhere from 4 to 63 days (cases 1, 2, 3, 5, 9, 10, 11, 14, 16, 17, 21). Ten cases did not have adequate information on the hospitalization/death timeframe (cases 4, 6-8, 12, 13, 15, 19, 20). Among cases where the clinical outcome was known, fatality was 100% (cases 1-7, 9-11, 14-21). Three cases had unknown outcomes (cases 8, 12, 13).

Thirty-nine cases of *Balamuthia* GAE in the United States have been published in case reports or cited in summary compilations. [See Appendix A, Table 4 for all

Balamuthia GAE case references.] Eleven case reports did not include information that lent evidence of predisposing health factors, nor was the patient's status stated as being healthy (cases 3, 4, 6, 9, 23-25, 30, 31, 35, 36). Nine cases were reported as being previously healthy before becoming ill (cases 7, 10, 12, 13, 15, 20, 21, 27, 32). In instances where predisposing health factors were known, nine cases had otitis, pharyngitis, or some other type of respiratory illness (cases 2, 5, 11, 14, 18, 19, 22, 33, 37). Five cases had a history of alcohol or drug abuse (cases 5 [also had TB as noted above], 8, 17, 26, 29,). Other predisposing health factors included: organ transplantation and immunosuppressive therapy (cases 34, 38, 39), HIV (case 16), prolonged steroid use (case 28), and diabetes (case 1).

Unlike *Acanthamoeba* GAE, the majority of cases of *Balamuthia* GAE were in males younger than the age of 18 years (n= 14; cases 2, 3, 9, 13-15, 18, 23, 24, 28, 30, 32, 36, 37) followed by adult males (n= 11; cases 5, 6, 8, 17, 25, 26, 29, 31, 33, 35, 39). There were eight case reports on females under age 18 (cases 4, 7, 10-12, 20-22) and five adult women (cases 1, 16, 19, 27, 38). One case report did not include any age or gender information (case 34). Fourteen of the cases (cases 7, 10, 15, 17, 21-25, 28-31, 36) were reported to be of Hispanic ethnicity; the rest of the case reports did not include information on ethnicity. Environmental exposure to soil was cited in six cases (cases 7, 25, 27, 30, 33, 35). Two patients cited gardening as a hobby (cases 27, 35), two had an occupational exposure to soil (case 25, 33), one cited motorcycling in the desert as a hobby (case 30), and one visited a farm (case 7). One case-patient had a history of frequent outdoor play in soil as well as exposure to an untreated well-water source for recreation and drinking (case 37). Three additional cases cited water exposure, one to a

freshwater pond (case 20), one to well water (case 1), and one to a lake (the latter may have also had soil exposure as the child of a migrant farmer, case 9). When timeframes were able to be determined, the number of days between suspected onset of symptoms and death ranged from 8 to 240 days (cases 1-5, 7, 10, 12-15, 17-19, 22, 24, 25, 33, 37, 38). Five cases resolved their infections and did not die (cases 21, 27, 31, 32, 39) and fourteen did not have adequate information on the symptom onset/death timeframe (cases 6, 8, 9, 11, 16, 20, 23, 26, 28, 29, 30, 34, 35, 36). The number of days between hospitalization and death ranged anywhere from 3 to 120 days (cases 1, 2, 9, 11, 16, 20, 26, 28-30, 35, 36). Twenty-two cases did not have adequate information on the hospitalization/death timeframe (cases 3-8, 10, 12-15, 17-19, 22-25, 33, 34, 37, 38). Survival for those with *Balamuthia* GAE was slightly better for those with GAE caused by *Acanthamoeba* spp. Four patients are reported to have survived (case 21, 27, 31, 39) and the other 35 died (cases 1-20, 22-26, 28-30, 32-38).

Cutaneous acanthamoebiasis

Twelve cases of cutaneous acanthamoebiasis occurring in the United States have been reported in the literature and all cases were among immunocompromised adults. [See Appendix A, Table 5 for all cutaneous acanthamoebiasis case references.] The main predisposing medical condition was HIV/AIDS (n=10; cases 1-4, 6-11). The only other condition cited in the literature was immunosuppression due to organ transplantation (n=2; cases 5, 12). Nine of the case-patients were males (cases 1-7, 9, 10) and three were females (cases 8, 11, 12). Two case reports noted that the patients were of Hispanic ethnicity (cases 2, 8), but ethnicities were not reported for the other 10 case-patients. No soil exposures were cited in the case reports, although two reports noted cases had

freshwater exposure before skin lesions appeared (cases 6, 7). One case was noted to have a local creek nearby that was used as a domestic drinking water source (case 12). No potential environmental exposures were cited for the remaining nine case-patients. When timeframes could be determined, the number of days between suspected onset of symptoms and death ranged from 22 to 450 days (cases 1-4, 6, 8-11). Two cases resolved their infections and did not die (cases 5, 12) but the symptom onset/death timeframes could not be determined and one fatal case did not have adequate information on the symptom onset/death timeframe (case 7). The only report of number of days hospitalized was in a survivor who was hospitalized for approximately 150 days (case 12). The remaining cases did not have adequate information on the hospitalization/death or hospitalization/discharge timeframes (cases 1-11). There were three reported survivors of cutaneous *Acanthamoeba* (cases 5, 11, 12) and the other nine cases resulted in death (cases 1-4, 6-11).

Acanthamoeba rhinosinusitis

Two cases of *Acanthamoeba rhinosinusitis* have been reported in the literature. [See Appendix A, Table 6 for all *Acanthamoeba rhinosinusitis* case references.] Both patients were immunocompromised adults, one male (case 1) and one female (case 2). The male had HIV and recurrent sinus problems and the female had undergone a bilateral lung transplantation due to a progressive lung disease. Both of these patients are reported to have resolved their infections at 4 (case 1) and 3 (case 2) weeks respectively, but no further follow-up was mentioned in either article.

Acanthamoeba osteomyelitis

A lone case of *Acanthamoeba osteomyelitis* was reported in 1981 in a 32-year-old

pre-diabetic woman. [See Appendix A, Table 7 for all *Acanthamoeba* osteomyelitis case references.] She had a mass in the right mandibular area, which was removed and replaced with a bone graft. A subsequent surgery was necessary in order to remove necrotic bone. Inflammatory exudate from bone marrow in the necrotic bone was positive for *Acanthamoeba*. The report does not cite any follow-up after the patient's surgery for necrotic bone removal, so it is not known if she continued to improve and remain ameba-free (case 1). Three other cases of *Acanthamoeba* osteomyelitis have been reported in the literature, but all of these case patients had disseminated *Acanthamoeba* infection (see Appendix A, Table 1, cases 17, 18, 27).

Survivors: Acanthamoeba

There have been nine reports of successful treatment of acanthamoebiasis: three disseminated (Appendix A, Table 1, cases 17, 23, 24), three cutaneous (Appendix A; Table 4, cases 5, 11, 12), two rhinosinusitis (Appendix A, Table 5, cases 1, 2), and one osteomyelitis (Appendix A, Table 6, case 1). There have been four published cases where the clinical outcome was unknown due to lack of information in the reports: one was a disseminated disease case (Appendix A, Table 1, case 22) and three were GAE cases (Appendix A, Table 3, cases 8, 12, 13). In 1998, a report was published of a 7-year-old male with HIV who had been diagnosed with cutaneous *Acanthamoeba* disease at 5 ½ years of age (Appendix A, Table 1, case 17). Initially this case-patient was treated with fluconazole without complete resolution of his skin lesions. Several months after his diagnosis of cutaneous *Acanthamoeba* disease, he had a painful thumb and testing showed osteomyelitis without a definitive cause. He was given pentamidine daily over the course of a month and then maintained on itraconazole with monthly treatments of

pentamidine. By the time he was 6-years-old, he was diagnosed with granulomatous amebic osteomyelitis after presenting with a swollen elbow. He was again given pentamidine daily for one month. His cutaneous lesions and osteomyelitis recurred when he was close to 7 years old, despite maintenance therapy. Daily pentamidine for one month was given in combination with 5-fluorocytosine (5-FC). The child was then maintained on 5-FC and antiretroviral treatment and was alive at the time of publication but had occasional new skin lesions.

In 1999 a report was published of a 39-year-old woman who had undergone a lung transplant six years earlier (Appendix A, Table 1, case 23). She was reported to have presented with skin nodules, with new nodules continuing to develop over the next several days. Multiple biopsies were performed before a diagnosis of *Acanthamoeba* was finally made. Initial treatment included a combination of 5-FC and pentamidine, as well as topical treatment with chlorhexidine gluconate and ketoconazole cream. Upon going into respiratory failure and requiring mechanical ventilation, the patient's bronchoalveolar lavage (BAL) was found to be positive for *Acanthamoeba*. At this point azithromycin was added to her drug regimen and it appears she stayed on this regimen for close to a month, at which time her skin lesions were improving and her BAL was negative. However, she began to have side effects that resulted in several of the medications being discontinued. The patient had abnormal liver function tests and a biopsy showed *Acanthamoeba* was present in this organ, so the patient was given lower doses of pentamidine and 5-FC was restarted. On discharge, the patient was still being treated with 5-FC and clarithromycin was added. The woman showed no evidence of infection 12 months after her hospital discharge.

In 2002, a 37-year-old AIDS and cancer patient was reported to have nasal obstruction that did not resolve with antibiotic treatment (Appendix A, Table 1, case 24). He subsequently developed papular lesions on his extremities. Multiple biopsies were inconclusive, although Cytomeglovirus was suspected and treatment was begun; the patient did not respond well. Subsequently, the nasal obstruction became worse until the patient needed surgery, at which point a diagnosis of *Acanthamoeba* was made from the specimens obtained during surgery. The patient was given pentamidine and topical treatments of both chlorhexidine and ketoconazole. When he had side effects due to pentamidine it was discontinued and 5-FC was begun; this regimen was continued for a month with successful resolution of his disease. At the time of the report, the patient was still taking itraconazole but there was no evidence of recurrence. The report does not mention when treatment with this drug was begun.

Three cases of cutaneous acanthamoebiasis were reported to have survived. In 1992, a 31-year-old man who had undergone a kidney transplant presented with skin nodules (Appendix A, Table 5, case 5). Upon diagnosis of *Acanthamoeba* via positive skin biopsies, he was given intravenous (IV) pentamidine and topical treatment with chlorhexidine and ketoconazole. He was treated with pentamidine for 4 weeks, although the dosage had to be reduced due to an elevated creatinine level. At discharge from hospital, his previous medications were discontinued and he was then treated with oral itraconazole. He continued to take this medicine at a reduced dosage for at least two years after his diagnosis without recurrence of infection.

In 2004, a 51-year-old woman with AIDS presented with skin papules, photophobia, and headache (Appendix A, Table 5, case 11). Based on a skin biopsy, she

was diagnosed with cutaneous *Acanthamoeba* disease and underwent a CT scan and lumbar puncture, which were subsequently negative for evidence of central nervous system involvement. Her treatment regimen included pentamidine and 5-FC, but new skin nodules continued to appear so sulfadiazine and highly active antiretroviral treatment (HAART) were added. After 14 days of pentamidine once a day, pentamidine was discontinued and the patient was continued on maintenance therapy of 5-FC, sulfadiazine, and HAART. The patient was still free of CNS involvement 3 months after release from the hospital with slow improvement of her skin lesions, possibly due to inconsistent compliance with her treatment.

Also in 2004, a 52-year-old woman who had a lung transplant three years earlier and remained on immunosuppressive therapy presented with nodules on her trunk and lower extremities (Appendix A, Table 5, case 12). She was diagnosed with cutaneous *Acanthamoeba* disease and unsuccessfully treated with itraconazole and metronidazole for two weeks. CDC and an infectious disease specialist were consulted and the woman was started on IV amphotericin B lipid complex and voriconazole. She was discharged on the same medications delivered through an outpatient service. Her treatment with these two drugs lasted 10 weeks before the dosage and frequency were changed and IV voriconazole was switched to oral voriconazole. After her discharge she was maintained on oral voriconazole for 5 months with resolution of her skin lesions and no recurrence.

Two cases of *Acanthamoeba* rhinosinusitis were reported to have survived their infections. A 45-year-old man with HIV had sinus difficulties over the course of a year which necessitated multiple sinus surgeries before he was finally diagnosed with *Acanthamoeba* rhinosinusitis (Appendix A, Table 6, case 1). He had a subtotal

septectomy, used gentamycin nasal rinses for 4 weeks and was maintained on oral itraconazole. No timeframe was given for the maintenance therapy, nor was the time frame between the resolution of the infection and the publication of the paper given. In 2005, a 49-year-old woman who had undergone a lung transplant was reported to have survived *Acanthamoeba* rhinosinusitis (Appendix A, Table 6, case 2). Seven months after transplantation she had sinus difficulties and after diagnosis was treated with amphotericin, voriconazole, and caspofungin. Three weeks after treatment began she underwent a sinus debridement, but no *Acanthamoeba* were seen in specimens from this debridement: she remained *Acanthamoeba* free in the month following which is as long as the report states the patient was followed.

The only other published report of an *Acanthamoeba* survivor was in 1981 (Appendix A, Table 7, case 1). A 32-year-old female was diagnosed with amebic osteomyelitis after a sequestrum of necrotic bone was removed from her jaw. The patient does not appear to have been treated with drugs that were specific to resolving *Acanthamoeba* infections. She was given IV penicillin, used betadine mouthwash after surgery, and was discharged. The authors do not discuss long-term follow up, but as she was reported as still alive at the time of the published report she is counted among the survivors in this review. As with many of these cases where patients were reported to have survived, it is difficult to determine if there were later recurrences or if patients truly resolved their infections and never relapsed.

Survivors: Balamuthia

There have been six reports of successful treatment of balamuthiasis, one with disseminated disease (Appendix A, Table 2, case 4) and five with *Balamuthia* GAE

(Appendix A, Table 4, cases 21, 27, 31, 32, 39). A 64-year-old man who previously had a skin lesion that was biopsied with pending results presented with neurological difficulties (Appendix A, Table 2, case 4). Lesions were seen in the parietal area of his brain on both a CT scan and a MRI. He subsequently underwent a brain biopsy and was released 10 days later. He was then re-hospitalized and received a diagnosis of *B. mandrillaris* disseminated disease as *Balamuthia* organisms were identified in both the brain tissue and the skin biopsy. He was treated with 5-FC, fluconazole, IV pentamidine, sulfadiazine, and azithromycin (which was later switched to clarithromycin). The patient was ventilated and in intensive care for seven weeks. He was discharged to a rehabilitation unit and fluconazole was discontinued. Following a relapse, fluconazole was added again and he was maintained on fluconazole and sulfadiazine over the course of five years. The patient did recover enough to be able to walk, perform activities of daily living and communicate well.

There have been five reports of survivors who were diagnosed with *Balamuthia* GAE. Three of the case-patients were reported as previously healthy (Appendix A, Table 4, cases 21, 27, 32) and one had an unknown health status (Appendix A, Table 4, case 31). A report published in 2003 discusses a 5-year-old girl who, 48 days after initial presentation, was diagnosed with *Balamuthia* GAE (Appendix A, Table 4, case 21). The patient underwent several combinations of treatment. Initially she was treated with ketoconazole and metronidazole for 34 days. These medications were then discontinued and she was placed on clarithromycin and flucytosine for 14 days. Her treatment was subsequently changed again and included azithromycin, fluconazole, pentamidine, and thioridazine. Over the course of the next two-and-a-half years, her treatment varied,

primarily because of discontinuation of medications due to side effects and initiation of medicines due to seizures. More than two-and-a-half years after her first hospital admission she was still maintained on clarithromycin and fluconazole.

In 2004, a report was published of a 72-year-old woman who underwent a brain biopsy that was positive for *Balamuthia* (Appendix A, Table 4, case 27). The biopsy was excisional, and upon diagnosis, the patient was treated with pentamidine (IV), sulfadiazine, fluconazole, and clarithromycin. The patient remained asymptomatic, but it is unknown how much time elapsed between the case and the published report as well as how long she was maintained on therapy. In 2007 a *Balamuthia* GAE survivor was reported (Appendix A, Table 4, case 31). The report only stated that the patient was living at the time of his last report to a physician, but he was lost to follow-up.

In 2010, a report of a 2-year-old boy with GAE was published (Appendix A, Table 4, case 32). He was initially treated for tuberculosis but underwent a biopsy and was given a diagnosis of *Balamuthia*. He was treated with pentamidine, fluconazole, flucytosine, sulfadiazine, clarithromycin, and thioridazine. The boy was placed on a ventilator and required a ventriculoperitoneal shunt. He was maintained on a ventilator for almost two months and then transferred to a rehabilitation unit. Over the course of at least 22 months, the case-patient was given clarithromycin, sulfadiazine, flucytosine, and fluconazole without evidence of an active infection. After time in the rehabilitation unit, the boy was able to follow simple commands, had improved postural stability, and was attempting to speak. MRIs show that the lesions decreased in size and number.

The most recent report of a *Balamuthia* GAE survivor was published in 2010 (Appendix A, Table 4, case 39). A kidney transplant recipient who acquired his infection

through organ transplantation from an infected donor survived the infection, although he spent two months in a coma. He slowly regained cognitive and motor functions and entered a rehabilitation unit. He had residual neurologic effects such as right arm paralysis and bilateral leg weakness. He also had intermittent vision loss. No treatment regimen was included in the publication.

Ethnicity

In 2004, a letter to the editor of *Emerging Infectious Diseases* was published, suggesting that Hispanic ethnicity may be a risk factor for *Balamuthia* GAE.²⁰ The primary authors of this letter were involved with the California Encephalitis Project (CEP), which was begun in 1998 with the purpose of assisting clinicians in the State with cases of encephalitis by offering enhanced diagnostic testing for infectious agents. The CEP collects serum and other samples from patients in California that have presented with encephalitis, and a subset of these samples were pulled for *Balamuthia* screening. The criteria for screening included: case history that had clinical or laboratory information suggestive of *Balamuthia* GAE and either an outdoor occupational exposure or other outdoor recreational activity that might have lead to exposure to soil. Of 215 samples tested, three were positive for *Balamuthia*. Four additional samples, not a part of the CEP, were also tested and were found to be positive. All seven cases were healthy Hispanic Americans who died of GAE. The CEP contacted CDC to obtain information about their records of *Balamuthia* cases, and it was determined that based on either case report identification of ethnicity or a traditional Hispanic last name, about 50%, or 25, of the U.S. case patients with known or suspected ethnicity were Hispanic Americans. No information was given on the number of cases with truly unknown ethnicities, just that

there were approximately 50 U.S. cases at the time of publication. This same letter also stated that 36% of *Balamuthia* GAE cases occurred in Latin American countries.²⁰

CHAPTER III: METHODS AND PROCEDURES

CDC's Free-Living Ameba (FLA) Laboratory collects information on cases of suspected *Balamuthia* and non-keratitis *Acanthamoeba* diseases as part of their contact with physicians and laboratorians who are seeking assistance with diagnosis. The head of the FLA Laboratory, Dr. Govinda Visvesvara, has been working with free-living amoebae since 1964 and has been with the FLA Laboratory since 1974. He was the first scientist to isolate and subsequently name *Balamuthia mandrillaris* and is considered one of the world's FLA experts, with more than 250 publications on the subject. The FLA Laboratory is one of the only research laboratories in the United States performing reference diagnostic testing for free-living amoebae, and the lab handles specimens tested through various methods such as staining of histopathologic slides, culture, and polymerase chain reaction (PCR). The FLA Laboratory is one of only two known labs currently performing an antibody test (indirect immunofluorescence or IIF) for the free-living amoebae; the other laboratory is at the California Department of Health Services, which runs the California Encephalitis Project (CEP). These two labs have historically shared data. Therefore, the FLA Laboratory holds records for most of the non-*Acanthamoeba* keratitis and *Balamuthia mandrillaris* FLA cases diagnosed in the United States. It is for this reason that a review of FLA laboratory records supplemented with a review of the published literature should capture the majority of FLA cases diagnosed in the United States, even though diseases associated with the free-living amoebae are not nationally notifiable.

Data for this study were abstracted onto case report forms from CDC laboratory

and clinical consultation files for positive cases of *Balamuthia* and non-keratitis *Acanthamoeba* that occurred in the United States. See Appendix B for a copy of the case report form. Data in the files ranged greatly in content from laboratory specimen submission forms with little information about the patient's clinical course to copies of extensive medical records and autopsies.

A literature review was also performed to collect all published cases and media reports of *Balamuthia* and non-keratitis *Acanthamoeba* disease occurring in the U.S. The published cases were then compared to the CDC-diagnosed cases to determine which ones referred to the same patients. This was done in three ways: matching similar patient clinical and laboratory data, matching authors with contact clinicians or laboratorians, and consulting with Dr. Govinda Visvesvara, the aforementioned head of the FLA Laboratory. Information from published case reports took precedence over CDC records when there was conflicting data, unless the publication conflicted with a final autopsy report in CDC files. CDC records took precedence over any information found in the general media. In instances where there was information on length of time but not specific dates for illness onset, hospitalization, and/or time from illness onset to death, dummy dates were entered for the purpose of calculating durations.

In instances where published cases could not be matched with CDC cases, the diagnostic methods for the published cases were reviewed. Cases tested by the following agencies/individuals were considered to be reputable cases based on their known diagnostic methods: the California Department of Health Services; Dr. Eddy Willaert, Institute of Tropical Medicine in Antwerp, Belgium; Dr. Julio Martinez, University of Pittsburgh; Dr. Bruce Torian, Idaho; Dr. Gregory Booten, Ohio State University. If it

was not apparent that a published case was in CDC records, or if one of the laboratories above was not cited, individual cases were discussed with Dr. Visvesvara to determine if he was familiar with the case. Diagnostic and clinical features of the published case were reviewed to determine if the case likely fit a diagnosis of acanthamoebiasis or balamuthiasis.

Each case-patient identified from these records and/or the literature review was assigned a unique identifier consisting of a prefix of AC for *Acanthamoeba* or BA for *Balamuthia*, followed by a two digit number representing the calendar year in which the case first presented with symptoms (when known) or was either first reported to CDC or published in the literature. A case number in sequential order from 001 to infinity was designated as the last three digits of the unique identifier. Case information was then entered into a limited-user database that serves as a resource for CDC clinical consultation and surveillance.

The database has 976 variables and contains both quantitative and qualitative data. A major issue with the database is that many of the variables are set up as true/false, complicating the calculation of denominators for certain areas of data. The database allows exportation of files in Excel format and splits the database information into eight separate files when exporting: demographics, exposure history, medical history, current illness, laboratory tests, histopathology, diagnostic imaging, and diagnostic and treatment outcomes. For the purposes of this study, the information was stripped of identifiers prior to analysis. The data were then analyzed using SPSS.

Exported data were split into separate files for *Acanthamoeba* and *Balamuthia*. Each of the eight database files for each organism were imported into SPSS, labeled and

assigned type, values, and measures. All eight files were also combined for each organism for instances where information in the separate databases needed to be examined together. Data were first explored by examination of frequencies, ranges and means, and cross tabulations. Research question 1 was answered using these methods, and frequencies, ranges, and means were used for research question 4. For research question 2, frequencies were also used, but because acanthamoebiasis has so many manifestations, it was useful to explore the data by disease manifestation. Therefore, case summaries were run using final diagnosis as the grouping variable and presenting symptoms in the variables column. Research question 3 was also examined using case summaries with the survived variable as the grouping variable and treatment drugs in the variables column. Medications given to the survivors were visualized using Excel spreadsheets to determine commonalities in the drugs used and duration. Although the methods used above answered the research questions, I also further analyzed some of the demographic, exposure history, previous medical history, and outcomes data to try to glean further information about these diseases and produced epidemiologic curves for all reported cases of acanthamoebiasis and balamuthiasis in the United States through 2009.

38.8 years of age; 7% (n=8/110) were children younger than 18 years of age, 87% (n=96/110) were adults 18-64 years of age, and 6% (n=6/110) were 65 years of age or older. Males were 73% of cases (n=82/112) and females were 27% (n=30/112); two cases had missing information. See Figure 3 for an epidemic curve by age of *Acanthamoeba* spp. [Appendix C has a larger version of this figure.] Also see Figure 4 for the geographic distribution of *Acanthamoeba* spp. cases by state of treatment.

Figure 3: Epidemic Curve by Age for Cases of *Acanthamoeba* spp.—United States, 1955-2009




Figure 4: Geographic Distribution of Non-Keratitis *Acanthamoeba* spp. Cases by State of Treatment




Figure 6: Geographic Distribution of *Balamuthia mandrillaris* Cases by State of Treatment




Table 1: Summary of Demographic Data for Non-Keratitis *Acanthamoeba* spp. and *Balamuthia mandrillaris* Cases

Variable		<i>Acanthamoeba</i> (N=114)		<i>Balamuthia</i> (N=70)	
		Data	Missing	Data	Missing
Race	White	63% (27/43)	62% (71/114)	58% (19/33)	53% (37/70)
	African American	35% (15/43)		36% (12/33)	
	American Indian	2% (1/43)		0% (0/33)	
	Asian/Pacific Islander	0% (0/43)		6% (2/33)	
Ethnicity	Hispanic	82% (9/11)	90% (103/114)	76% (22/29)	59% (41/70)
	Non-Hispanic	18% (2/11)		24% (7/29)	
Immigration	Immigrant	75% (6/8)	93% (106/114)	36% (4/11)	84% (59/70)
	Non-Immigrant	25% (6/8)		64% (7/11)	
Age	Range	8 m–79 y	4% (4/114)	4 m–89 y	3% (2/70)
	Mean	38.8 years		30.4 years	
Sex	Male	73% (82/112)	2% (2/114)	65% (45/69)	1% (1/70)

Presenting Symptoms: Research Question 2

Patients presented with a variety of non-descriptive symptoms for both *Acanthamoeba* and *Balamuthia* disease. Fever and headache were the two most common symptoms shared by those with either disease. See Tables 2 and 3 for the top ten symptoms patients presented with upon examination or hospitalization for illness caused by *Acanthamoeba* spp. and *Balamuthia mandrillaris* respectively.

Table 2: Top Ten Presenting Symptoms of Patients Later Diagnosed With Non-Keratitis *Acanthamoeba* spp. Infection (N=95/114)

Presenting Symptom	No. of Cases Reporting Symptoms
Other General Symptoms*	39
Fever	34
Headache	29
Sinus problems	18
Other Neurologic Deficit**	17
Lethargy/Fatigue	13
Confusion	9
Weight Loss	8
Weakness	7
Altered Mental Status	6
Cough	6
Nausea	6
Vomiting	6

*Other general symptoms include but were not limited to: chills (n=7/39), facial swelling/pain/tenderness (n=5/39), epistaxis (n=3/39), jaundice (n=2/39), night sweats (n=2/39), and incontinence (n=2/39).

** Other neurologic symptoms include but are not limited to: Romberg's sign (n=1/17), Babinski sign (n=1/17), Kernig's sign (n=1/17), Brudzinkin's sign (n=1/17).

Table 3: Top Ten Presenting Symptoms of Patients Later Diagnosed With *Balamuthia mandrillaris* Infection (N=63/70)

Presenting Symptom	No. of Cases Reporting Symptoms
Fever	23
Headache	18
Lethargy/Fatigue	18
Vomiting	18
Other General Symptoms*	16
Other Neurologic Deficit**	15
Seizures	14

Weakness	13
Other Visual Symptoms	11
Altered Mental Status	10
Hemiparesis	9
Ataxia	8

*Other general symptoms include but were not limited to: incontinence (n=3/16), neck pain (n=2/16), and loss of appetite (n=2/16).

** Other neurologic symptoms include but are not limited to: Babinski sign (n=2/15), and unresponsiveness (n=2/15).

Because both acanthamoebiasis and balamuthiasis have multiple disease manifestations, a further exploration was done looking at presenting symptoms by disease manifestation. Symptoms were broken up into four categories: general presenting symptoms (17 variables), visual symptoms (4 variables), neurologic symptoms (29 variables), and skin lesions (4 variables). Cases that had no information for every variable in a category were taken out of the frequency counts and treated as unknowns. Remaining cases may have had more than one symptom in each of the four presenting symptom categories. In the case of the skin lesions category, knowns included those cases who indicated they had skin lesions or did not have skin lesions. After analysis it was apparent that not all of the possible variables for the symptom categories were selected as symptoms upon presentation. See Tables 4-7 for breakdowns of *Acanthamoeba* cases; see table footnotes for numbers of variables not chosen in each category.

Table 4: Presenting General Symptoms for Cases of Non-Keratitis *Acanthamoeba* spp. Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=30/36)*	Other General Symptoms	19
	Fever	12
	Sinus problems	11
	Headache	10
	Lethargy/Fatigue	5
	Cough	4

	Nausea	3
	Weight Loss	3
	Shortness of breath	2
	Vomiting	1
	Stiff Neck	1
GAE (n=25/48)*	Fever	16
	Headache	14
	Other General Symptoms	14
	Lethargy/Fatigue	7
	Vomiting	4
	Nausea	3
	Weight Loss	3
	Diarrhea	2
	Anorexia	1
	Cough	1
	Shortness of Breath	1
	Sinus Problems	1
Cutaneous (n=10/23)*	Fever	5
	Headache	3
	Other General Symptoms	4
	Diarrhea	2
	Weight Loss	2
	Myalgia	2
	Sinus Problems	2
	Shortness of Breath	1
	Lethargy/Fatigue	1
Rhinosinusitis (n=4/6)*	Sinus Problems	4
	Fever	1
	Headache	1
	Other General Symptoms	1
Osteomyelitis (n=1/1)	Other General Symptoms	1

*Those reporting multiple general symptoms on initial presentation included: 19 GAE cases, 24 disseminated cases, two rhinosinusitis cases, and six cutaneous cases.

Although it was possible to select up to 17 variables for presenting general symptoms, three of those variables were not selected among those cases who reported presenting symptoms.

Table 5: Presenting Visual Symptoms for Cases of Non-Keratitis *Acanthamoeba* spp. Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=3/36)*	Blurred Vision	2
	Diplopia	1
	Other Visual Symptom	1
GAE (n=5/48)*	Blurred Vision	2
	Diplopia	2
	Other Visual Symptom	2
	Photophobia	1
Cutaneous (n=2)	Photophobia	2

*Those reporting multiple visual symptoms on initial presentation included: two GAE cases and one disseminated case.

Table 6: Presenting Neurologic Symptoms for Cases of Non-Keratitis *Acanthamoeba* spp. Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=12/36)*	Confusion	5
	Other Neurologic Deficit	4
	Weakness	3
	Altered Mental Status	3
	Behavioral Changes	1
	Dysphagia	1
	Hallucinations	1
	Seizures	1
	Hemiparesis	1
GAE (n=22/48)*	Other Neurologic Deficit	12
	Weakness	4
	Hemiparesis	3
	Seizures	3
	Confusion	3
	Altered Mental Status	2
	Aphasia	2
	Ataxia	2
	Numbness or Facial Numbness	1
	Hyperreflexia	1
	Nystagmus	1

Cutaneous (n=2/23)	Other Neurologic Deficit	1
	Altered Mental Status	1

*Those reporting multiple neurologic symptoms included: 10 GAE cases and four disseminated cases.

Although it was possible to select up to 29 variables for presenting neurologic symptoms, 15 of those variables were not selected among those cases who reported presenting symptoms.

Table 7: Presenting Skin Lesions for Cases of *Acanthamoeba* spp. Infection by Disease Manifestation

Disease Manifestation	Type of Skin Lesion	No. of Known Cases Reporting Symptoms
Disseminated (n=34/36)*	Other Type	16
	Ulcers	7
	Erythematous Nodules	6
	No Skin Lesions	7
GAE (n=7/48)	Other Type	3
	Ulcers	1
	No Skin Lesions	3
Cutaneous (n=23/23)*	Other Type	9
	Erythematous Nodules	7
	Ulcers	5
	Type Not Stated	4
Rhinosinusitis (n=2/6)	Ulcers	1
	No Skin Lesions	1

*Those reporting multiple types of skin lesions on initial presentation included: four disseminated cases and two cutaneous cases.

Although it was possible to select up to 4 variables for presenting skin lesions, one of those variables were not selected among those cases who reported presenting symptoms.

Although the manifestations of balamuthiasis appear to be limited to GAE and disseminated infection, which potentially have similar presenting symptoms, a breakdown by disease manifestation and the same four presenting symptom categories was done for cases of *Balamuthia mandrillaris*. This allows for an examination of any similarities or differences in manifestations as well as a comparison to *Acanthamoeba* GAE and disseminated disease. *Balamuthia* cases that had no information for any

variable in a category were taken out of the frequency counts and treated as unknowns. Remaining cases may have had more than one symptom in each of the 4 presenting symptom categories. See Tables 8-11 for presenting symptoms of *Balamuthia* GAE and disseminated balamuthiasis.

Table 8: Presenting General Symptoms for Cases of *B. mandrillaris* Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=5/8)*	Headache	3
	Nausea	2
	Vomiting	2
	Other General Symptoms	2
	Fever	1
	Diarrhea	1
	Weight Loss	1
	Stiff Neck	1
	Disorientation	1
	Lethargy/Fatigue	1
GAE (n=41/62)*	Fever	20
	Vomiting	16
	Headache	15
	Lethargy/Fatigue	15
	Other General Symptoms	14
	Nausea	5
	Anorexia	3
	Stiff neck	2
	Disorientation	2
	Diarrhea	1

*Those reporting multiple general symptoms on initial presentation included: 25 GAE cases and three disseminated cases.

Although it was possible to select up to 17 variables for presenting general symptoms, four of those variables were not selected among those cases who reported presenting symptoms.

Table 9: Presenting Visual Symptoms for Cases of *B. mandrillaris* Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=1/8)	Other Visual Symptom	1

GAE (n=13/62)*	Other Visual Symptom	10
	Diplopia	4
	Photophobia	1

*Those reporting multiple visual symptoms on initial presentation included: two GAE cases.

Although it was possible to select up to 4 variables for presenting visual symptoms, one of those variables were not selected among those cases who reported presenting symptoms.

Table 10: Presenting Neurologic Symptoms for Cases of *B. mandrillaris* Infection by Disease Manifestation

Disease Manifestation	Presenting Symptom	No. of Known Cases Reporting Symptoms
Disseminated (n=5/8)*	Other Neurologic Deficit	3
	Hemiparesis	2
	Seizures	2
	Altered Mental Status	1
	Aphasia	1
	Confusion	1
	Hallucinations	1
	Weakness	1
GAE (n=48/62)*	Other Neurologic Deficit	12
	Weakness	12
	Seizures	12
	Altered Mental Status	9
	Ataxia	8
	Hemiparesis	7
	Behavioral Changes	6
	Aphasia	5
	Confusion	4
	Cranial Nerve Deficit VI	3
	Other Cranial Nerve deficit	3
	Cranial Nerve Deficit VII	2
	Dysphagia	1
	Facial Numbness	1
	Hallucinations	1
	Combativeness	1
	Hyperreflexia	1
	Loss of Balance	1
Nystagmus	1	

Those reporting multiple neurologic symptoms on initial presentation included: 22 GAE cases and five disseminated cases.

Although it was possible to select up to 29 variables for presenting neurologic symptoms, 10 of those variables were not selected among those cases who reported presenting symptoms.

Table 11: Presenting Skin Lesions for Cases of *B. mandrillaris* Infection by Disease Manifestation

Disease Manifestation	Type of Skin Lesion	No. of Known Cases Reporting Symptoms
Disseminated (n=4/8)	Other type	3
	Ulcers	1
GAE (n=17/62)	Other type	3
	No Skin Lesions	14

Although it was possible to select up to 4 variables for presenting skin lesions, two of those variables were not selected among those cases who reported presenting symptoms.

In looking at a comparison of the top five presenting general symptoms for disseminated acanthamoebiasis and balamuthiasis (Table 12), three of the top five were the same. The differences were that disseminated acanthamoebiasis cases reported sinus problems and lethargy/fatigue and disseminated balamuthiasis did not. But *Balamuthia* cases experienced vomiting and nausea frequently enough to be in the top five general symptoms. For presenting neurologic symptoms, the top five symptoms were similar for both disseminated diseases but varied in that disseminated acanthamoebiasis cases reported behavioral changes and dysphagia. Disseminated acanthamoebiasis cases reported more visual symptoms more types of skin lesions than disseminated balamuthiasis cases.

Table 12: Comparison of Top Five Presenting Symptoms for Disseminated *Acanthamoeba* and *Balamuthia* Disease

General Symptoms			
<i>Acanthamoeba</i> (n=30/36)		<i>Balamuthia</i> (n=5/8)	
Presenting symptom	No. of Known Cases Reporting Symptoms	Presenting symptom	No. of Known Cases Reporting Symptoms
Other General	19	Headache	3

Symptoms			
Fever	12	Nausea	2
Sinus Problems	11	Vomiting	2
Headache	10	Other General Symptoms	2
Lethargy/Fatigue	5	Fever	2
Neurologic Symptoms			
<i>Acanthamoeba</i> (n=12/36)		<i>Balamuthia</i> (n=5/8)	
Confusion	5	Other Neurologic Symptom	3
Other Neurologic Symptom	4	Hemiparesis	2
Weakness	3	Seizures	2
Altered Mental Status	3	Altered Mental Status, Aphasia, Confusion, Hallucinations, Weakness	Each symptom had a count of 1
Behavioral Changes, Dysphagia, Hallucinations, Seizures, Hemiparesis	Each symptom had a count of 1		
Visual Symptoms			
<i>Acanthamoeba</i> (n=3/36)		<i>Balamuthia</i> (n=1/8)	
Blurred Vision	2	Other Visual Symptom	1
Diplopia	1		
Other Visual Symptom	1		
Skin Lesions			
<i>Acanthamoeba</i> (n=34/36)		<i>Balamuthia</i> (n=4/8)	
Other Type	16	Other Type	3
Ulcers	7	Ulcers	1
Erythematous Nodules	6		
No Skin Lesions	7		

In comparing the top five presenting general symptoms for *Acanthamoeba* and *Balamuthia* GAE (Table 13), four of the five were the same. The only difference was that *Acanthamoeba* GAE cases reported nausea, whereas *Balamuthia* GAE cases reported vomiting. The presenting neurologic symptoms also differed somewhat, with 3 of the 5 being the same, but *Acanthamoeba* GAE cases reported hemiparesis and confusion, whereas *Balamuthia* GAE cases indicated having altered mental status and ataxia. *Acanthamoeba* GAE case-patients reported blurred vision where as *Balamuthia* GAE case-patients did not; *Balamuthia* GAE case-patients reported a high number of other visual symptoms. Both had reports of skin lesions but they were not diagnosed as cutaneous disease manifestations of *Acanthamoeba* or *Balamuthia*.

Table 13: Comparison of Top Five Presenting Symptoms for *Acanthamoeba* and *Balamuthia* GAE

General Symptoms			
<i>Acanthamoeba</i> (n=25/48)		<i>Balamuthia</i> (n=41/62)	
Presenting symptom	No. of Known Cases Reporting Symptoms	Presenting symptom	No. of Known Cases Reporting Symptoms
Fever	16	Fever	20
Headache	14	Vomiting	16
Other General Symptom	14	Headache	15
Lethargy/Fatigue	7	Lethargy/Fatigue	15
Nausea	4	Other General Symptom	14
Neurologic Symptoms			
<i>Acanthamoeba</i> (n=22/48)		<i>Balamuthia</i> (n=48/62)	
Other Neurologic Symptoms	12	Other Neurologic Symptoms	12
Weakness	4	Weakness	12
Hemiparesis	3	Seizures	12
Seizures	3	Altered Mental Status	9
Confusion	3	Ataxia	8
Visual Symptoms			

<i>Acanthamoeba</i> (n=5/48)		<i>Balamuthia</i> (n=13/62)	
Blurred Vision	2	Other Visual Symptom	10
Diplopia	2	Diplopia	4
Other Visual Symptom	2	Photophobia	1
Photophobia	1		
Skin Lesions			
<i>Acanthamoeba</i> (n=5/48)		<i>Balamuthia</i> (n=13/62)	
Other Type	3	Other Type	3
Ulcers	1	No Skin Lesions	14
No Skin Lesions	3		

Treatment: Research Question 3

The survivors of *Acanthamoeba* infection were cases whose disease manifestations were cutaneous, rhinosinusitis or disseminated infection, typically involving skin and sinuses. There has not been a reported case of *Acanthamoeba* GAE, or disseminated acanthamoebiasis with GAE involvement, that has survived. Among the survivors of *Acanthamoeba* disease of those with known outcomes (n=9/86), there was no common drug used in all cases; however, five cases took itraconazole and four cases took pentamidine (Table 14). Drug commonalities by *Acanthamoeba* disease manifestation are also summarized in Table 14. Non-survivors also took many of the same drugs. Cases that had no information for any drug listed in the database, or that had unknown outcomes, were taken out of the frequency counts and treated as unknowns. Among *Balamuthia* survivors (n=6), there were also no common drugs used in all cases, although fluconazole and pentamidine was used in all but one instance (Table 15). Drug commonalities by *Balamuthia* disease manifestation are also summarized in Table 15. Again, non-survivors also took many of the same drugs.

Table 14: Drugs in Common for Non-Keratitis *Acanthamoeba* Survivors Compared to Non-Survivors

	Drug	No. of Survivors With Known Treatment	No. of non-Survivors with Known Treatment
All manifestations	Itraconazole*	5/9	6/47
	Pentamidine	4/9	11/47
	Ketoconazole	3/9	6/47
	Chlorhexidine topical	3/9	3/47
	Amphotericin B	2/9	14/47
	Flucytosine	2/9	6/47
	Voriconazole	2/9	5/47
Disseminated	Itraconazole	2/3	4/21
	Ketoconazole	2/3	3/21
	Pentamidine	2/3	5/21
	Chlorhexidine topical	2/3	1/21
GAE		No Survivors	
Cutaneous	Itraconazole	2/3	2/7
	Pentamidine	2/3	4/7
Rhinosinusitis		No Drugs in Common for Survivors (n=2)	
Osteomyelitis		1 case	

Table 15: Drugs in Common for *Balamuthia* Survivors Compared to Non-Survivors

	Drug	No. of Survivors With Known Treatment	No. of non-Survivors with Known Treatment
All manifestations	Fluconazole*	5/6	7/40
	Pentamidine*	5/6	6/40
	Clarithromycin*	4/6	1/40
	Sulfadiazine*	4/6	6/40
	Flucytosine*	4/6	4/40
	Azithromycin*	3/6	3/40
	Ketaconazole	2/6	0/40
Disseminated		1 case	
GAE	Azithromycin	2/5	3/35

	Clarithromycin	3/5	1/35
	Fluconazole	4/5	5/35
	Flucytosine	3/5	4/35
	Pentamidine	4/5	5/35
	Sulfadiazine	3/5	4/35

See Appendix C for depictions of treatment regimens over time for survivors.

Duration of Illness: Research Question 4

For case-patients who were diagnosed as having *Acanthamoeba* sp. infection and who were known to have died (n=77/114), 49% (n=38/77) had missing information on the number of days between illness onset and death. Of the decedents with known durations of illness (n=39/77), the mean duration of for illness (onset until death) was 101. The range was from 3 to 765 days. For case-patients with *Balamuthia* infections who were known to have died (n=61/70), 39% (n=24/61) had missing information on the number of days between illness onset and death. Of the decedants with known durations of illness (n=37/61) the mean duration of illness (onset until death) was 74 days, with a range of 8 days to 568 days. Based on the data that was seen during the collection and abstraction work, it appeared that the timing of diagnosis was often quite late in the course of illness or post-mortem.

Further Data Analysis

Exposures

There was a substantial lack of exposure data for both *Acanthamoeba* and *Balamuthia* cases. Only 6% (n=7/114) of *Acanthamoeba* cases had information about water exposure, six had exposures and one did not. Only 4% (n=4/114) had information about soil exposures; all four cases reportedly had exposure. One case reported an occupational exposure where the individual worked with animals. Only 20% (n=23/114)

of *Acanthamoeba* cases had information about travel and only two out of these included information about their travel. One case-patient reportedly visited Mexico and one was noted to have “traveled extensively,” with no further details provided.

Only 17% (n=12/70) *Balamuthia* cases had information about water exposures; nine had exposures and three did not. Only 20% (n=14/70) had information about soil exposure; 12 cases had known exposures whereas two did not. Fifteen (21%) had occupational exposure information with four reporting actual occupations (three were farmers/ranchers or living on a farm, one was a firefighter). Half (n=35/70) of the cases had information about travel history and, of those, 12 gave travel location information and 23 did not. The country cited most frequently in the travel history was Mexico (7 cases).

Medical History

HIV status was reported for 58% (n=66/114) of *Acanthamoeba* cases; a minimum of 52% (n=59/114) of patients who became infected with *Acanthamoeba* spp. had HIV. Patients’ AIDS status was known for 53% of cases (n=60/114); a minimum of 47% (n=54/114) of patients with *Acanthamoeba* disease had AIDS, of which 81% (n=44/54) had CD4 counts or another illness that indicated AIDS and 19% (n=10/54) did not.

Past medical history data, when available, also showed a variety of respiratory illnesses, other immunocompromising conditions, and prescription and illegal drug use, all of which might have predisposed patients to infection with *Acanthamoeba* spp. (Table 16). Twelve cases had no information on past medical history.

Table 16: Past Medical Conditions That May Be Predisposing Factors for Non-Keratitis *Acanthamoeba* spp. Infection (N=102/114)

	No. of Cases Reporting Condition
Respiratory Conditions	
Pneumonitis	30
Sinusitis	14
Other	5
Deviated Septum	2
TB	2
Nasal Surgery	1
Pharyngitis	1
Immunocompromising Conditions	
HIV	59
Organ transplant	22
Cancer	18
Diabetes	8
Renal failure	7
Alcohol misuse	5
Lymphoproliferative disease	5
Other autoimmune disease	4
Systemic lupus erthematosus	3
Other hematologic disease	3
Cirrohosis	1
Treatment/drugs	
Steroid use	17
Immunosuppressants	16
Eye Infections	7
Illegal drug use	6
Excessive antibiotic use	1
Skin infections	1

Because HIV/AIDS seemed to be so frequent among the *Acanthamoeba* cases, a further breakdown of other immunocompromising illnesses was done by HIV status. See Table 17.

Table 17: Positive Non-Keratitis *Acanthamoeba* Patients Reporting Another Immunocompromising Condition by HIV Status

Immunocompromising Conditions	No. of HIV-Positive Cases Reporting Another Condition (n=7/59)*	No. of HIV-Negative Cases Reporting Another Condition (n=7/7)**	No. of HIV Unknown Cases Reporting Another Condition (n=27/48)***
Cancer	3	2	13
Alcohol Misuse	2	2	1
Other Hematologic Disease	2	0	1
Renal failure	1	1	5
Other Autoimmune Disease	1	1	2
Organ Transplant	0	5	17
Diabetes	0	2	6
Systemic Lupus Erythematosus	0	1	2
Lymphoproliferative Disease	0	0	4
Cirrhosis	0	0	1

*Two HIV-positive *Acanthamoeba* cases had multiple immunocompromising conditions.

**Five HIV-negative cases had multiple immunocompromising conditions.

*** Eighteen cases had multiple immunocompromising conditions.

Other hematologic disease included: end-stage renal disease, hemophilia, and myelodysplastic syndrome.

Other autoimmune disease included: progressive transverse myelitis, graft vs. host disease, hemolytic anemia, and discoid lupis; hypogammaglobulinemia.

Unlike *Acanthamoeba* spp. infection, *Balamuthia* cases did not typically have HIV. Fifty-six percent of cases had an unknown HIV status (n=39/70). Of the 31 cases with a known status, only 26% (n=8/31) were HIV positive and 74% (n=23/31) were negative. Of the eight cases that had HIV, four had progressed to AIDS. See Table 18 for previous medical history that may predispose patients to infection with *Balamuthia mandrillaris*. Twenty-four cases had no information on past medical conditions.

Table 18: Past Medical Conditions That May Be Predisposing Factors for *Balamuthia mandrillas* Infection (N=46/70)

	No. of Cases Reporting Condition
Respiratory Conditions	
Otitis	6
Pharyngitis	3
Pneumonitis	3
TB	3
Other	2
Deviated Septum	1
Nasal surgery	1
Sinusitis	1
Immunocompromising Conditions	
Alcohol misuse	9
HIV	8
Diabetes	4
Organ transplant	3
Renal failure	3
Other hematologic disease	2
Cirrohosis	1
Treatment/drugs	
Illegal drug use	14
Skin infections	3
Steroid use	3

Initial and Final Diagnoses and Outcomes

Seventy-eight percent of *Acanthamoeba* cases had missing data for admitting diagnosis (n=89/114). Rarely, 8% of the time, were cases diagnosed with meningitis (n=1/25) or meningoencephalitis (1/25): such cases were typically diagnosed as other illness (92%, n=23/25) such as toxoplasmosis (n=3/23), toxoplasmosis vs. or with lymphoma (n=3/23), or vasculitis (n=3/23). The remaining initial diagnoses (n=14/23) were varied. Final diagnosis of *Acanthamoeba* cases are shown below in Table 19.

Table 19: Final Diagnosis of Cases of Non-Keratitis *Acanthamoeba* spp. Infection

	No. of Cases	Percent
<i>Acanthamoeba</i> GAE	48	42%
Disseminated acanthamoebiasis	36	32%
<i>Acanthamoeba</i> rhinosinusitis	6	5%

Cutaneous acanthamoebiasis	23	20%
Other: <i>Acanthamoeba</i> osteomyelitis	1	1%
Total	114	100%

Forty percent of *Balamuthia* cases had missing data for admitting diagnosis (n=28/70).

As with *Acanthamoeba* infection, *Balamuthia* cases were rarely (26%, n=12/42) diagnosed with encephalitis (n=3/12), meningitis (n=6/12), or meningoencephalitis (n=3/12) on initial presentation, and more commonly diagnosed with other illnesses (74%, n=30/42) such as cysticercosis/neurocysticercosis (n=3/30), toxoplasmosis (n=3/30), stroke (n=2/30), neoplasia (n=3/30), or acute disseminated encephalomyelitis (ADEM) (n=2/30). The remaining initial diagnoses (n=25/30) were varied. Final diagnosis of *Balamuthia* cases are shown below in Table 20.

Table 20: Final Diagnosis of Cases of *Balamuthia mandrillaris* Infection

	No. of Cases	Percent
<i>Balamuthia</i> GAE	62	89%
Disseminated balamuthiasis	8	11%
Total	70	100%

Outcomes for both *Acanthamoeba* and *Balamuthia* infections were poor. Twenty-eight cases of *Acanthamoeba* had unknown outcomes (25%, n=114). Of the cases with known outcomes, 10% of case-patients survived (n=9/86) and 90% died (n=77/86). Prognosis for those with *Balamuthia* infection was similar. Three cases had unknown outcomes (4%, n=70). Of the cases with known outcomes, 9% survived (n=6/67) survived and 91% died (n=61/67).

CHAPTER V: DISCUSSION AND CONCLUSION

In examining the demographics of both *Acanthamoeba* and *Balamuthia* cases, the fact that the disease manifestations are far more common in men than women was one of the only conclusions that could be drawn from the data. The completeness of answers for this question was almost 100% in both *Acanthamoeba* and *Balamuthia* datasets.

Similarly, the data on age was more than 96% complete for both groups. The vast majority (87%) of *Acanthamoeba* cases occurred in adults aged 18–64 years with a mean age of 38.8 years. However, the pattern for *Balamuthia* cases tended towards younger persons; while most (47%) were still adults 18–64 years of age, a large proportion of *Balamuthia* cases (43%) occurred in children younger than 18 years of age.

The scarcity of ethnicity data makes it difficult to interpret an epidemiologic pattern of this variable. More than 90% of the ethnicity data for *Acanthamoeba* cases was missing. While 82% (n=9/11) of patients with known ethnicity were Hispanic, a denominator of 11 is insufficient to draw conclusions. For *Balamuthia* cases, 59% of the ethnicity data was unknown. As with *Acanthamoeba* case-patients, while Hispanics did make up the majority, 76% (n=22/29), when the ethnicity of the *Balamuthia* case-patients was known, a denominator of 29 may not be enough to draw conclusions from. Schuster, Glaser, Honarmand, Maguire, and Visvesvara (2004) proposed that Hispanics may be at increased risk for *Balamuthia mandrillaris* infection based on the results of seven positive tests, all in Hispanic patients, conducted by the California Encephalitis Project (CEP) and because 8 of 11 cases in the State occurred in Hispanic Americans.²⁰ The

authors also searched CDC records and state that “approximately 50% of the 50 North American patients” were Hispanic; this number is potentially biased as it is based on the assumption that certain surnames were ethnically Hispanic. Also, because the California State Health Department has the CEP, data from that state may over-represent Hispanics because there are a high number of persons of that ethnicity in the state (37% based on U.S. Census estimates in 2009).²⁹

However, some suggestion of an ethnicity bias is present in the *Balamuthia* data. This thesis also examined case records at CDC and in the published literature. In looking at the national proportion of Hispanic ethnicity in 1999, the median year of the *Balamuthia* dataset, it was 11.5%.³⁰ Even though the ethnicity was unknown for 41 *Balamuthia* case-patients, 22 (31%) of the total *Balamuthia* cases (n=70) were of known Hispanic ethnicity, which is already greater than the population proportion. And while the suggestion that balamuthiasis might be more common in Hispanics versus non-Hispanics may be true, the cause of this possible association is unknown and might reflect a number of factors, possibly including different exposure patterns.

In looking at the geographic distribution of cases, there is no apparent pattern by state of treatment, with cases being treated in all regions of the continental United States. For both *Acanthamoeba* and *Balamuthia*, those states reporting more cases tended to be the states with larger State health departments. Although exposure patterns might be different in some states, it's worth considering that the large number of cases reported in California might be due to its ongoing CEP. Similarly the large number of cases from Texas might be because of its proximity to and awareness of the CEP's work. Because the CEP conducts active surveillance on cases of encephalitis, it may be that the numbers

of free-living ameba cases from California and Texas indicate that cases are more frequent than supposed and are being diagnosed because the cause of encephalitis is being closely looked at.

Presenting symptom information is not encouraging in terms of gaining a better understanding of how to more rapidly suspect and thereby diagnosis and treat free-living amebae infection. Much of the presenting symptom information was missing from cases diagnosed with *Acanthamoeba* GAE, ranging from 48% missing on general symptoms to 90% missing visual symptoms. Gaps in visual symptom and neurologic symptom data were also apparent for disseminated acanthamoebiasis cases and in each symptom category for cutaneous cases, with the exception of presenting skin lesions. Even among the cutaneous cases, the type of lesion seen on presentation was highly variable and not pathognomonic. While both *Acanthamoeba* GAE and disseminated acanthamoebiasis had fever and headache as the predominant general symptoms and other neurologic deficits and weakness were typical neurologic symptoms, these symptoms and signs are rather vague symptoms and can indicate many types of illness. It may be that there are specific neurologic deficits that could stand out if the data were more complete.

In contrast, cases diagnosed with *Balamuthia* GAE or disseminated balamuthiasis had better completion of data for both presenting general symptoms (34% missing) and neurologic symptoms (23% missing). Similar to *Acanthamoeba*, headache was common among GAE and disseminated cases, but vomiting also was high on the list of common symptoms, with fever more evident in GAE cases than in disseminated cases. Interestingly, unlike *Acanthamoeba*, infection with *Balamuthia* was not noted to have any symptoms related to sinus problems, nor were there documented cases of *Balamuthia*

rhinosinuitis. Also there were no standalone cases of cutaneous balamuthiasis, and skin manifestations only occurred in cases of disseminated infections. All disseminated cases had granulomatous amebic encephalitis and a second disease manifestation (most often skin), whereas disseminated infections of acanthamoebiasis were more varied in their manifestations with only 11 of the 30 cases having proven GAE.

The generality of signs and symptoms for both *Acanthamoeba* and *Balamuthia* are reflected in the initial diagnoses. Although the data were limited, the classical diagnoses for headaches and fevers (i.e., meningitis, encephalitis, and meningoencephalitis) were not commonly made. Rather, other diagnoses were more common, including: parasitic diseases (e.g., toxoplasmosis, cysticercosis, neurocysticercosis), neoplasias, vasculitis, or stroke. The variables other neurologic symptoms, other general symptoms, and other visual symptoms should be more closely examined to determine if there any signs or symptoms for these variables that suggest a unique symptom for free-living ameba infection.

Examination of the treatment regimens in survivors of acanthamoebiasis shows that while there were several common drugs administered to the survivors, the same drugs were used in non-survivors. A closer examination of the combination of drugs used needs to be done to determine if there is a combined therapy that is more effective. Balamuthiasis differs in that the two manifestations of the disease reported have always involved the central nervous system. As with acanthamoebiasis, drugs in common usage for the survivors were often used in non-survivors. Again, closer examination of the combination of drugs used needs to be done. Duration and dosage are also important factors, but unfortunately much of the dosage information or dosage timing is missing

from this retrospective review. So going forward in data collection for an informal surveillance system of free-living amebas, it is essential that accurate treatment information is collected for closer examination of whether or not certain drugs are more effective than others.

The mean number of days from illness onset to death for cases of *Balamuthia mandrillaris* was 74 and for *Acanthamoeba* spp. was 100 days. This seems to indicate that there is sufficient time to make a correct diagnosis, but further evaluation of the data is necessary to examine the timing of hospitalization, timing of a correct diagnosis, and timing of treatment specific to free-living amoeba infection. If it is determined that sufficient time exists for a correct diagnosis, then the question becomes how to increase awareness of these infections so they are included in a differential diagnosis when patients present with symptoms that tend to be very common to various forms of meningitis, and where other potential diagnoses such as toxoplasmosis, neurocysticercosis, and tumors are often considered far more quickly.

Outside of the main research questions, much of the other data explored was inconclusive. The epidemic curve for *Acanthamoeba* spp. infection shows the highest number of cases between 1994 and 1997 with an apparent drop off in reported cases after 2003. Because the infection is rare, this is difficult to interpret. The increase of cases in the 1990s is likely due to greater awareness of the infection and increased requests to the Centers for Disease Control and Prevention for diagnostic assistance. Are the cases really decreasing, or are other laboratories beginning to perform diagnostic testing and therefore CDC is not receiving specimens or reports? It is important to continue to monitor cases to see if there truly is this drop in cases or if the number of infections

remains relatively constant over time. Because *Balamuthia* was not recognized as the cause of human infections until around 1990, the epidemic curve is not particularly surprising, with some fluctuations throughout the 1990s and then a seeming increase in cases in more recent years, again likely due to greater awareness of free-living ameba infections.

The exposure data were too scarce to draw conclusions from in terms of modes of transmission (i.e., water, soil). While persons with *Naegleria fowleri* often have a history of swimming and recreational water activities in freshwater, persons with *Acanthamoeba*, where exposure history was known, had both water and soil exposures, as did those with *Balamuthia*. The types of water bodies, water conditions, and recreational water activities are data that are not known in these cases.

The data did strongly support the supposition that *Acanthamoeba* infection disproportionately affect immunocompromised persons. Outside of those with HIV, it appears that steroids and immunosuppressant drugs may be important conditions. Although not necessarily associated with immunosuppression, a history of pneumonitis also seemed to be common. This might reflect a compromised portal of entry for the pathogens or perhaps pneumonitis is a common co-morbidity in those *Acanthamoeba* patients with AIDS. The past medical history for *Balamuthia mandrillaris* cases is less revealing, although drug and alcohol abuse appeared to be a relatively common potentially immunosuppressive condition as well as a variety of respiratory conditions.

The data exploration for this thesis was limited and the data collected for CDC's informal surveillance system for free-living amebas has more information to be accessed and analyzed. It will be important, as noted above, to look closer at the timing of onset,

hospitalization, diagnosis, and death or survival in hope that there may be some information that might be useful in improving clinical outcomes. Because so little data on U.S. cases is available, fewer than 200 cases with much missing data, it is crucial to gather as much information as possible about exposure, presentation, and treatment of future cases. This exploration has been the first comprehensive look at all known cases of *Acanthamoeba* and *Balamuthia* infection in 20 years and it contributes to a broader understanding of these illnesses.

REFERENCES

1. Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. *FEMS Immunol Med Microbiol* 2007;50:1-26.
2. Schuster FL, Visvesvara GS. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. *Int J Parasitol* 2004;34:1001-27.
3. 6 die from brain-eating amoeba after swimming. Associated Press, 2007. (Accessed March 17, 2011, at <http://www.msnbc.msn.com/id/32027560/>.)
4. Deadly Brain-Eating Amoeba Strikes. WebMD, 2008. (Accessed March 17, 2011, at <http://www.cbsnews.com/stories/2008/05/30/health/webmd/main4138705.shtml>.)
5. Marciano-Cabral F, MacLean R, Mensah A, LaPat-Polasko L. Identification of *Naegleria fowleri* in domestic water sources by nested PCR. *Appl Environ Microbiol* 2003;69:5864-9.
6. Visvesvara GS, Stehr-Green JK. Epidemiology of free-living ameba infections. *J Protozool* 1990;37:25S-33S.
7. Dunnebacke TH, Schuster FL, Yagi S, Booton GC. Isolation of *Balamuthia* amebas from the environment. *J Eukaryot Microbiol* 2003;50 Suppl:510-1.
8. Schuster FL, Dunnebacke TH, Booton GC, et al. Environmental isolation of *Balamuthia mandrillaris* associated with a case of amebic encephalitis. *J Clin Microbiol* 2003;41:3175-80.
9. Finnin PJ, Visvesvara GS, Campbell BE, Fry DR, Gasser RB. Multifocal *Balamuthia mandrillaris* infection in a dog in Australia. *Parasitol Res* 2007;100:423-6.
10. Foreman O, Sykes J, Ball L, Yang N, De Cock H. Disseminated infection with *Balamuthia mandrillaris* in a dog. *Vet Pathol* 2004;41:506-10.
11. Marciano-Cabral F, Cabral GA. The immune response to *Naegleria fowleri* amebae and pathogenesis of infection. *FEMS Immunol Med Microbiol* 2007;51:243-59.
12. Culbertson CG, Smith JW, Minner JR. *Acanthamoeba*: observations on animal pathogenicity. *Science* 1958;127:1506.
13. Butt CG. Primary amebic meningoencephalitis. *N Engl J Med* 1966;274:1473-6.
14. Jager BV, Stamm WP. Brain abscesses caused by free-living amoeba probably of the genus *Hartmannella* in a patient with Hodgkin's disease. *Lancet* 1972;2:1343-5.
15. Willaert E, Stevens AR, Healy GR. Retrospective identification of *Acanthamoeba culbertsoni* in a case of amoebic meningoencephalitis. *J Clin Pathol* 1978;31:717-20.
16. Visvesvara GS, Martinez AJ, Schuster FL, et al. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. *J Clin Microbiol* 1990;28:2750-6.
17. Martinez AJ. Is *Acanthamoeba* encephalitis an opportunistic infection? *Neurology* 1980;30:567-74.
18. *Balamuthia mandrillaris* transmitted through organ transplantation --- Mississippi, 2009. *MMWR Morb Mortal Wkly Rep* 2010;59:1165-70.
19. Notes from the field: transplant-transmitted *Balamuthia mandrillaris* --- Arizona, 2010. *MMWR Morb Mortal Wkly Rep* 2010;59:1182.
20. Schuster FL, Glaser C, Honarmand S, Maguire JH, Visvesvara GS. *Balamuthia* amebic encephalitis risk, Hispanic Americans. *Emerg Infect Dis* 2004;10:1510-2.

21. Martinez AJ, Garcia CA, Halks-Miller M, Arce-Vela R. Granulomatous amebic encephalitis presenting as a cerebral mass lesion. *Acta Neuropathol* 1980;51:85-91.
22. Rosenberg AS, Morgan MB. Disseminated acanthamoebiasis presenting as lobular panniculitis with necrotizing vasculitis in a patient with AIDS. *J Cutan Pathol* 2001;28:307-13.
23. Gordon SM, Steinberg JP, DuPuis MH, Kozarsky PE, Nickerson JF, Visvesvara GS. Culture isolation of *Acanthamoeba* species and leptomyxid amebas from patients with amebic meningoencephalitis, including two patients with AIDS. *Clin Infect Dis* 1992;15:1024-30.
24. Dunand VA, Hammer SM, Rossi R, et al. Parasitic sinusitis and otitis in patients infected with human immunodeficiency virus: report of five cases and review. *Clin Infect Dis* 1997;25:267-72.
25. Yoder JS, Eddy BA, Visvesvara GS, Capewell L, Beach MJ. The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. *Epidemiol Infect* 2010;138:968-75.
26. Kernohan JW, Magath TB, Schloss GT. Granuloma of brain probably due to *Endolimax williamsi* (*Iodamoeba butschlii*). *Arch Pathol* 1960;70:576-80.
27. Gullett J, Mills J, Hadley K, Podemski B, Pitts L, Gelber R. Disseminated granulomatous acanthamoeba infection presenting as an unusual skin lesion. *Am J Med* 1979;67:891-6.
28. Duma RJ, Helwig WB, Martinez AJ. Meningoencephalitis and brain abscess due to a free-living amoeba. *Ann Intern Med* 1978;88:468-73.
29. Estimates of the Resident Population by Race and Hispanic Origin for the United States and States: July 1, 2009. U.S. Government, 2009. (Accessed April 1, 2011, 2011, at <http://www.census.gov/popest/states/asrh/SC-EST2009-04.html>.)
30. Resident Population Estimates of the United States by Sex, Race, and Hispanic Origin: April 1, 1990 to July 1, 1999 with Short-Term Projection to November 1, 2000. U.S. Government, 2001. (Accessed April 9, 2011, 2011, at <http://www.census.gov/popest/archives/1990s/nat-srh.txt>.)
31. Sotelo-Avila C, Taylor FM, Ewing CW. Clinical-pathological conference. Primary amebic meningoencephalitis in a healthy 7-year-old boy. *J Pediatr* 1974;85:131-6.
32. Jones DB, Visvesvara GS, Robinson NM. *Acanthamoeba polyphaga* keratitis and *Acanthamoeba* uveitis associated with fatal meningoencephalitis. *Trans Ophthalmol Soc U K* 1975;95:221-32.
33. Martinez AJ, Sotelo-Avila C, Garcia-Tamayo J, Moron JT, Willaert E, Stamm WP. Meningoencephalitis due to *Acanthamoeba* SP. Pathogenesis and clinico-pathological study. *Acta Neuropathol* 1977;37:183-91.
34. Steinberg JP, Galindo RL, Kraus ES, Ghanem KG. Disseminated acanthamebiasis in a renal transplant recipient with osteomyelitis and cutaneous lesions: case report and literature review. *Clin Infect Dis* 2002;35:e43-9.
35. Grunnet ML, Cannon GH, Kushner JP. Fulminant amebic meningoencephalitis due to *Acanthamoeba*. *Neurology* 1981;31:174-6.
36. Martinez AJ. Acanthamoebiasis and immunosuppression. Case report. *J Neuropathol Exp Neurol* 1982;41:548-57.

37. Gonzalez MM, Gould E, Dickinson G, et al. Acquired immunodeficiency syndrome associated with *Acanthamoeba* infection and other opportunistic organisms. *Arch Pathol Lab Med* 1986;110:749-51.
38. Smith JH, Rotterdam HZ, Christie JD, et al. Infectious and inflammatory diseases. *Mod Pathol* 1990;3:223-33.
39. Sison JP, Kemper CA, Loveless M, McShane D, Visvesvara GS, Deresinski SC. Disseminated *acanthamoeba* infection in patients with AIDS: case reports and review. *Clin Infect Dis* 1995;20:1207-16.
40. Carter WW, Gompf SG, Toney JF, Greene JN, Cutolo EP. Disseminated *Acanthamoeba* sinusitis in a patient with AIDS: a possible role for early antiretroviral therapy. *AIDS Read* 2004;14:41-9.
41. Wiley CA, Safrin RE, Davis CE, et al. *Acanthamoeba* meningoencephalitis in a patient with AIDS. *J Infect Dis* 1987;155:130-3.
42. Murakawa GJ, McCalmont T, Altman J, et al. Disseminated *acanthamebiasis* in patients with AIDS. A report of five cases and a review of the literature. *Arch Dermatol* 1995;131:1291-6.
43. Cugino L, Butcher J, Hoppes WL, Doyle M, Bogden C. *Acanthamoeba* sinusitis in a patient with AIDS [abstract no. 451]. In: 1995 IDSA Annual Meeting; 1995: *Clin Infect Dis*; 1995. p. 795.
44. Tan B, Weldon-Linne CM, Rhone DP, Penning CL, Visvesvara GS. *Acanthamoeba* infection presenting as skin lesions in patients with the acquired immunodeficiency syndrome. *Arch Pathol Lab Med* 1993;117:1043-6.
45. Gardner HA, Martinez AJ, Visvesvara GS, Sotrel A. Granulomatous amebic encephalitis in an AIDS patient. *Neurology* 1991;41:1993-5.
46. Friedland LR, Raphael SA, Deutsch ES, et al. Disseminated *Acanthamoeba* infection in a child with symptomatic human immunodeficiency virus infection. *Pediatr Infect Dis J* 1992;11:404-7.
47. Anderlini P, Przepiorka D, Luna M, et al. *Acanthamoeba* meningoencephalitis after bone marrow transplantation. *Bone Marrow Transplant* 1994;14:459-61.
48. Helton J, Loveless M, White CR, Jr. Cutaneous *acanthamoeba* infection associated with leukocytoclastic vasculitis in an AIDS patient. *Am J Dermatopathol* 1993;15:146-9.
49. Schwarzwald H, Shah P, Hicks J, Levy M, Wagner ML, Kline MW. Disseminated *Acanthamoeba* infection in a human immunodeficiency virus-infected infant. *Pediatr Infect Dis J* 2003;22:197-9.
50. Selby DM, Chandra RS, Rakusan TA, Loechelt B, Markle BM, Visvesvara GS. Amebic osteomyelitis in a child with acquired immunodeficiency syndrome: a case report. *Pediatr Pathol Lab Med* 1998;18:89-95.
51. Levine S, Goldstein AE, Dahdouh M, Blank P, Hoffman C, Gropper CA. Cutaneous *Acanthamoeba* in a patient with AIDS: a case study with a review of new therapy; quiz 386. *Cutis* 2001;67:377-80.
52. Oliva S, Jantz M, Tiernan R, Cook DL, Judson MA. Successful treatment of widely disseminated *acanthamoebiasis*. *South Med J* 1999;92:55-7.
53. Teknos TN, Poulin MD, Laruentano AM, Li KK. *Acanthamoeba* rhinosinusitis: characterization, diagnosis, and treatment. *Am J Rhinol* 2000;14:387-91.

54. Kim SY, Syms MJ, Holtel MR, Nauschuetz KK. Acanthamoeba sinusitis with subsequent dissemination in an AIDS patient. *Ear Nose Throat J* 2000;79:168, 71-4.
55. Castellano-Sanchez A, Popp AC, Nolte FS, et al. Acanthamoeba castellanii encephalitis following partially mismatched related donor peripheral stem cell transplantation. *Transpl Infect Dis* 2003;5:191-4.
56. Rivera MA, Padhya TA. Acanthamoeba: a rare primary cause of rhinosinusitis. *Laryngoscope* 2002;112:1201-3.
57. Duarte AG, Sattar F, Granwehr B, Aronson JF, Wang Z, Lick S. Disseminated acanthamoebiasis after lung transplantation. *J Heart Lung Transplant* 2006;25:237-40.
58. Readinger A, Blumberg M, Colome-Grimmer MI, Kelly E. Disseminated Acanthamoeba infection with sporotrichoid nodules. *Int J Dermatol* 2006;45:942-3.
59. Hoffman EO, Garcia, C., Lunseth, J., McGarry, P., Coover, J. A case of Primary Amebic Meningoencephalitis: light and electron microscopy, and immunohistologic studies. *The American Journal of Tropical Medicine and Hygiene* 1978;27:29-38.
60. Anzil AP, Roa C, Wrzolek MA, Sher JH, Kozlowski PB. Acanthamebic meningoencephalitis in an AIDS patient -- an autopsy report. *J Neuropathol Exp Neurol* 1989;48:313.
61. Anzil AP, Rao C, Wrzolek MA, Visvesvara GS, Sher JH, Kozlowski PB. Amebic meningoencephalitis in a patient with AIDS caused by a newly recognized opportunistic pathogen. *Leptomyxid ameba*. *Arch Pathol Lab Med* 1991;115:21-5.
62. Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. *Clin Infect Dis* 2003;37:1304-12.
63. Bakardjiev A, Azimi PH, Ashouri N, et al. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. *Pediatr Infect Dis J* 2003;22:447-53.
64. Deol I, Robledo L, Meza A, Visvesvara GS, Andrews RJ. Encephalitis due to a free-living amoeba (Balamuthia mandrillaris): case report with literature review. *Surg Neurol* 2000;53:611-6.
65. Pritzker AS, Kim BK, Agrawal D, Southern PM, Jr., Pandya AG. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris presenting as a skin lesion. *J Am Acad Dermatol* 2004;50:S38-41.
66. Patras D, Andujar JJ. Meningoencephalitis due to Hartmannella (Acanthamoeba). *Am J Clin Pathol* 1966;46:226-33.
67. Robert VB, Rorke LB. Primary amebic encephalitis, probably from Acanthamoeba. *Ann Intern Med* 1973;79:174-9.
68. Kenney M. The Micro-Kolmer complement fixation test in routine screening for soil amoeba infection. *Health Lab Sci* 1971;8:5-10.
69. Robinson G, Wilson SE, Williams RA. Surgery in patients with acquired immunodeficiency syndrome. *Arch Surg* 1987;122:170-5.
70. Sell JJ, Rupp FW, Orrison WW, Jr. Granulomatous amebic encephalitis caused by acanthamoeba. *Neuroradiology* 1997;39:434-6.
71. Feingold JM, Abraham J, Bilgrami S, et al. Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation. *Bone Marrow Transplant* 1998;22:297-300.
72. Gene AH, Gardner PA, Couce Matovelle ME. Rapidly expanding brain mass. *Transpl Infect Dis* 2007;9:211-3.

73. Bloch KC, Schuster FL. Inability to make a premortem diagnosis of *Acanthamoeba* species infection in a patient with fatal granulomatous amebic encephalitis. *J Clin Microbiol* 2005;43:3003-6.
74. Uschuplich V, Mileusnic D, Johnson M. Pathologic quiz case. Progressive fatal encephalopathy in an immunosuppressed patient with a history of discoid lupus erythematosus. Subacute granulomatous meningoencephalitis (*Acanthamoeba culbertsoni*). *Arch Pathol Lab Med* 2004;128:e109-11.
75. McKellar MS, Mehta LR, Greenlee JE, et al. Fatal granulomatous *Acanthamoeba* encephalitis mimicking a stroke, diagnosed by correlation of results of sequential magnetic resonance imaging, biopsy, in vitro culture, immunofluorescence analysis, and molecular analysis. *J Clin Microbiol* 2006;44:4265-9.
76. MacLean RC, Hafez N, Tripathi S, Childress CG, Ghatak NR, Marciano-Cabral F. Identification of *Acanthamoeba* sp. in paraffin-embedded CNS tissue from an HIV+ individual by PCR. *Diagn Microbiol Infect Dis* 2007;57:289-94.
77. Cha JH, Furie K, Kay J, Walensky RP, Mullins ME, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness. *N Engl J Med* 2006;355:2678-89.
78. Cox EC. Amebic meningoencephalitis caused by *Acanthamoeba* species in a four month old child. *J S C Med Assoc* 1980;76:459-62.
79. Griesemer DA, Barton LL, Reese CM, et al. Amebic meningoencephalitis caused by *Balamuthia mandrillaris*. *Pediatr Neurol* 1994;10:249-54.
80. Wessel HB, Hubbard, J., Martinez, A.J., Willaert, E. Granulomatous amebic encephalitis (GAE) with prolonged clinical course, C.T. scan findings, diagnosis by brain biopsy, and effect of treatment. *Neurology* 1980;30:442.
81. Matson DO, Rouah E, Lee RT, Armstrong D, Parke JT, Baker CJ. *Acanthamoeba* meningoencephalitis masquerading as neurocysticercosis. *Pediatr Infect Dis J* 1988;7:121-4.
82. Neafie RC, Marty AM. Unusual infections in humans. *Clin Microbiol Rev* 1993;6:34-56.
83. Lowichik A, Rollins N, Delgado R, Visvesvara GS, Burns DK. Leptomyxid amebic meningoencephalitis mimicking brain stem glioma. *AJNR Am J Neuroradiol* 1995;16:926-9.
84. Poppek EJ, Neafie RC. Granulomatous meningoencephalitis due to leptomyxid ameba. *Pediatr Pathol* 1992;12:871-81.
85. Rowen JL, Doerr CA, Vogel H, Baker CJ. *Balamuthia mandrillaris*: a newly recognized agent for amebic meningoencephalitis. *Pediatr Infect Dis J* 1995;14:705-10.
86. Zagardo MT, Castellani RJ, Zoarski GH, Bauserman SC. Granulomatous amebic encephalitis caused by leptomyxid amebae in an HIV-infected patient. *AJNR Am J Neuroradiol* 1997;18:903-8.
87. Denney CF, Iragui VJ, Uber-Zak LD, et al. Amebic meningoencephalitis caused by *Balamuthia mandrillaris*: case report and review. *Clin Infect Dis* 1997;25:1354-8.
88. Healy JF. *Balamuthia* amebic encephalitis: radiographic and pathologic findings. *AJNR Am J Neuroradiol* 2002;23:486-9.

89. Duke BJ, Tyson RW, DeBiasi R, Freeman JE, Winston KR. Balamuthia mandrillaris meningoencephalitis presenting with acute hydrocephalus. *Pediatr Neurosurg* 1997;26:107-11.
90. Katz JD, Ropper AH, Adelman L, Worthington M, Wade P. A case of Balamuthia mandrillaris meningoencephalitis. *Arch Neurol* 2000;57:1210-2.
91. Li Q, Yang XH, Qian J. September 2004: a 6-year-old girl with headache and stiff neck. *Brain Pathol* 2005;15:93-5.
92. Bakardjiev A, Glaser C, Schuster F, Visvesvara GS. Three-year-old girl with fever and coma. *Pediatr Infect Dis J* 2002;21:75, 85-6.
93. Balamuthia amebic encephalitis--California, 1999-2007. *MMWR Morb Mortal Wkly Rep* 2008;57:768-71.
94. Yagi S, Booton GC, Visvesvara GS, Schuster FL. Detection of Balamuthia mitochondrial 16S rRNA gene DNA in clinical specimens by PCR. *J Clin Microbiol* 2005;43:3192-7.
95. Perez MT, Bush LM. Fatal amebic encephalitis caused by Balamuthia mandrillaris in an immunocompetent host: a clinicopathological review of pathogenic free-living amebae in human hosts. *Ann Diagn Pathol* 2007;11:440-7.
96. Jung S, Schelper RL, Visvesvara GS, Chang HT. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome. *Arch Pathol Lab Med* 2004;128:466-8.
97. Cary LC, Maul E, Potter C, et al. Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. *Pediatrics* 2010;125:e699-703.
98. Kansagra AP, Menon JP, Yarbrough CK, et al. Balamuthia mandrillaris meningoencephalitis in an immunocompromised patient. Case report. *J Neurosurg* 2009;111:301-5.
99. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. *Clin Infect Dis* 2007;44:204-12.
100. May LP, Sidhu GS, Buchness MR. Diagnosis of Acanthamoeba infection by cutaneous manifestations in a man seropositive to HIV. *J Am Acad Dermatol* 1992;26:352-5.
101. Iyengar V, Hefter LG, Park CH, Poretz DM, Simon ML, Colman L. Isolation of Acanthamoeba spp. from multiple cutaneous lesions of an AIDS patient [abstract 1092]. In: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Washington DC: American Society for Microbiology; 1992. p. 292.
102. Slater CA, Sickel JZ, Visvesvara GS, Pabico RC, Gaspari AA. Brief report: successful treatment of disseminated acanthamoeba infection in an immunocompromised patient. *N Engl J Med* 1994;331:85-7.
103. Migueles S, Kumar P. Primary cutaneous acanthamoeba infection in a patient with AIDS. *Clin Infect Dis* 1998;27:1547-8.
104. Hunt SJ, Reed SL, Mathews WC, Torian B. Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy. *Cutis* 1995;56:285-7.
105. Torno MS, Jr., Babapour R, Gurevitch A, Witt MD. Cutaneous acanthamoebiasis in AIDS. *J Am Acad Dermatol* 2000;42:351-4.

106. Chandrasekar PH, Nandi PS, Fairfax MR, Crane LR. Cutaneous infections due to *Acanthamoeba* in patients with acquired immunodeficiency syndrome. *Arch Intern Med* 1997;157:569-72.
107. Paltiel M, Powell E, Lynch J, Baranowski B, Martins C. Disseminated cutaneous acanthamebiasis: a case report and review of the literature. *Cutis* 2004;73:241-8.
108. Walia R, Montoya JG, Visvesvera GS, Booton GC, Doyle RL. A case of successful treatment of cutaneous *Acanthamoeba* infection in a lung transplant recipient. *Transpl Infect Dis* 2007;9:51-4.
109. Vernon SE, Acar BC, Pham SM, Fertel D. *Acanthamoeba* infection in lung transplantation: report of a case and review of the literature. *Transpl Infect Dis* 2005;7:154-7.
110. Borochoviz D, Martinez AJ, Patterson GT. Osteomyelitis of a bone graft of the mandible with *Acanthamoeba castellanii* infection. *Hum Pathol* 1981;12:573-6.

Appendix A: Detailed Tables of All Published Non-Keratitis *Acanthamoeba* and *Balamuthia* Cases

Table 1: Disseminated Acanthamoebiasis

Case (Ref)	Yr	State	Age (yr)	Sex	Race /Ethnicity	Health Status	Type of Illness	Clinical Course in Days*	Died
1 ^{21,27,31-33}	1972	TX	7	M	Black/Unknown	Pharyngitis, water & soil exposure	GAE, keratitis	~44 (s); 7 (h)	Y
2 ^{6,17,21,27,34}	1977	CA	24	F	Unknown/Hispanic	Unknown	GAE, skin, sinus, lymph node, adrenals, thyroid	~229 (s); ~49 (h)	Y
3 ^{6,35}	1978	UT	57	F	Unknown/Unknown	Systemic lupus erthematosus	GAE, lungs, skin	~8 (s); ~3 (h)	Y
4 ^{6,36}	1980	PA	38	M	White/Unknown	Kidney transplant	GAE, skin, pulmonary hyaline membrane	~43 (h); [Possibly 720 days (s)]	Y
5 ^{22,24,37-40}	1983	FL	29	M	Unknown/Unknown (Haitian)	AIDS	sinus, skin	~138 (s); 108 (h)	Y
6 ^{6,22,23,39,41}	1985	CA	34	M	Unknown/Unknown (Mexican American)	AIDS	GAE, skin	~9 (s); ~2 (h); [Possibly 374 days (s)]	Y
7 ^{6,40,42}	1987	CA	35	M	Black/Unknown	AIDS, PCP, IVDA	skin, keratitis, lungs	~92 after diagnosis; 8 (h)	Y
8 ^{6,24,43}	1989	OH	34	M	Unknown/Unknown	AIDS, recurrent otitis	skin, sinus	~210 (s)	Y
9 ^{6,22,23,44}	1989	IL	38	M	White/Unknown	AIDS, PCP	GAE, skin	~24 (h)	Y
10 ^{39,45}	1990	MA	39	M	Unknown/Unknown	AIDS	GAE, lungs	~8 (s); 4 (h)	Y
11 ^{22,24,39,40,46}	1990	PA	7	M	Unknown/Hispanic	HIV, demyelinating poly-neuropathy	skin, sinus	~193 (s)	Y

12 ⁴⁷	1991	TX	39	F	Unknown/ Unknown	CML, bone marrow transplant, pneumonia	GAE, lungs, adrenalitis	~25 (s)	Y
13 ^{22,24, 39,40,48}	1991	OR	33	M	Unknown/ Unknown	AIDS, PCP, sinusitis	skin, sinus	~123 (s) until lesions resolved, treatment con't for 8 mo. after	Y
14 ^{22,40, 42}	1992	CA	47	M	Unknown/ Hispanic	AIDS, PCP, HIV wasting sickness	skin, sinus	~120 (h)	Y
15 ^{22,40, 42}	1992	CA	36	M	American Indian/ Unknown	AIDS, PCP	skin, sinus	~120 (h)	Y
16 ^{40,49}	1993	TX	.8	M	Black/ Unknown	HIV	skin, lungs, lymph node, heart, kidney, spleen	~765 (s)	Y
17 ^{22,50}	1994	Unkn own	5	M	Black/ Unknown	HIV, PCP	skin, osteo- myelitis	~810 (s), with occasional skin lesions recurring	N
18 ^{22,40, 42}	1994	CA	45	M	White/ Unknown	AIDS, PCP, chronic sinusitis	skin, sinus, bone	~120 (h)	Y
19 ^{22,40, 42}	1994	CA	34	M	White/ Unknown	AIDS, PCP, chronic sinusitis	GAE, skin, sinus	~111 (s)	Y
20 ^{22,34, 47}	1994 ?	TX	32	F	Unknown/ Unknown	AML, bone marrow transplant, sinusitis	GAE, skin	~18 (s)	Y
21 ⁵¹	1995	NY	33	M	Black/ Unknown	AIDS, HIV- related cerebral atrophy	skin, sinus	~42 (s); tx for another 150 days until death	Y
22 ^{24,40}	1995	MA	37	M	Unknown/ Unknown	AIDS	skin, sinus	Min ~90 (s)	Unk now n
23 ^{34,52}	1997	SC	39	F	Black/ Unknown	Lung transplant	skin, liver, BAL	~124 (s); 118 (h)	N
24 ⁵³	2000	Unkn own	37	M	Unknown/ Unknown	AIDS, non- Hodgkins lymphoma	skin, sinus	~131, tx continued after with no evidence of recurrent infection	N

25 ^{40,54}	2000	Unkn own	42	M	Unknown/ Unknown	AIDS, peripheral neuropathy	sinus, lungs	~19 (s); 16 (h)	Y
26 ⁵⁵	2001	GA	45	M	Unknown/ Unknown	Acute myelogenous leukemia, stem cell transplant	GAE, lung	~98 (s); 3 (h)	Y
27 ³⁴	2001	MD	61	F	Unknown/ Unknown	Kidney transplant, renal failure	skin, bone	~26+ (h)	Y
28 ^{22,40, 56}	2001	FL	35	F	Unknown/ Unknown (Nicaragua n)	AIDS, recurrent sinus surgery	skin, sinus	Unknown	Y
29 ^{57,58}	2003	TX	60	M	White/Unk nown	Bilateral lung transplant; water exposure	GAE, skin, lung	~38 (s); 17 (h)	Y

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).

AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = *Pneumocystis carinii* pneumonia, IVDA = intravenous drug abuse; CML = chronic myelogenous leukemia; AML = acute myeloid leukemia

Table 2: Disseminated Balamuthiasis

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Type of Illness	Clinical Course in Days	Died
1 ^{6,17,59}	1975	LA	56	M	Black/ Unknown	Alcohol misuse, G6PD	GAE, pancreas	~27 (s); 13 (h)	Y
2 ^{6,16,23, 60,61}	1985	NY	36	M	Unknown/ Unknown	HIV, IVDA	GAE, kidney, adrenals	~25 (s); ~18 (h)	Y
3 ^{16,23}	1989	GA	52	M	Unknown/ Unknown	Amputation, soil exposure	GAE, cutaneous	~101 (s); ~77 (h)	Y
4 ⁶²	1996	CA	64	M	White/ Unknown	Ankylosing spondylitis, gardening	GAE, cutaneous	Unknown	N
5 ⁶³	1999	CA	2	F	Unknown/ Hispanic	Otitis media	GAE, lungs	~24 (s); 9 (h)	Y
6 ⁶⁴	1999	TX	38	M	Unknown/ Hispanic	IVDA	GAE, cutaneous	~568 (s); 19 (h)	Y
7 ⁶⁵	1999	TX	89	M	Unknown/ Unknown	Coronary artery disease, mild congestive heart failure	CSF, cutaneous	~390 (s); 13 (h)	Y

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).

HIV = Human Immunodeficiency Virus ; G6PD = glucose-6-phosphate dehydrogenase deficiency;
IVDA = intravenous drug abuse

Table 3: *Acanthamoeba* GAE

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Clinical Course in Days	Died
1 ^{6,17,21,26,27}	1955	AZ	6	F	Unknown/ Unknown	Unknown	~252 (s); 16 (h)	Y
2 ⁶⁶	1964	TX	59	M	Unknown/ Unknown	Drug abuse, cirrhosis	21 (h)	Y
3 ^{6,17,27,67}	1971	PA	58	M	Unknown/ Unknown	Alcohol abuse, pneumonia, water exposure	~21 (h)	Y
4 ^{6,27,68}	1971	NY	57	M	Unknown/ Unknown	History of stroke, intestinal amebiasis, water exposure	Unknown	Y
5 ^{6,14,15,17,27}	1972	NY?	27	M	White/ Unknown	Hodgkins, long-term immune-suppression, mild respiratory infections	31 (s); 5 (h)	Y
6 ^{6,17,21}	1976	LA	32	F	White/ Unknown	Pneumonitis	~43 (s)	Y
7 ⁶	1978	NY	11	F	Unknown/ Unknown	Unknown, soil exposure	Unknown	Y
8 ⁶	1978	TX	2	F	Unknown/ Unknown	Unknown	Unknown	Unknown
9 ^{6,22,23}	1981	GA	31	F	Unknown/ Unknown	Mixed connective tissue disorder	~40 (s); 9 (h)	Y
10 ^{6,23,39,69}	1985	CA	34	M	Unknown/ Unknown	HIV, PCP	~35 (s); ~28 (h)	Y
11 ^{6,23,39}	1987	GA	34	M	Unknown/ Unknown	AIDS, PCP	8 (s); 4 (h)	s
12 ⁶	1988	MN	60	M	Unknown/ Unknown	Unknown	Unknown	Unknown
13 ⁶	1988	SC	38	M	Unknown/ Unknown	Unknown	Unknown	Unknown
14 ^{23,39}	1990	GA	34	M	Unknown/ Unknown	AIDS, PCP	~15 (s); 8 (h)	Y
15 ⁷⁰	1997 ?	NM	35	M	Unknown/ Unknown	IVDA, alcohol abuse	~11 (s)	Y
16 ⁷¹	1997	CT	47	F	Unknown/ Unknown	Monocytoid B cell lymphoma, stem cell transplant	~143 (s); 11 (h)	Y
17 ⁷²	2003	PA	40	M	Unknown/ Unknown	Multiple visceral transplant, immune-suppressants	~14 (s); 12 (h)	Y
18 ^{73,74}	2003	TN	70	F	White/ Unknown	Discoid lupus erythematosus	~99 (s); 63 (h)	Y

19 ⁵	2004	Unkn won	51	M	White/ Unknown	Kidney transplant, diabetes, potential water exposure	~54 (s)	Y
20 ⁶	2005	VA	41	M	Black/ Unknown	HIV	~9 (s)	Y
21 ⁷⁷	2006 ?	MA	24	F	Unknown/ Unknown	Systemic lupus erythematosus, drug and alcohol dependency	~120 (s); 60 (h)	Y

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).

AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = *Pneumocystis carinii* pneumonia, IVDA = intravenous drug abuse

Table 4: *Balamuthia* GAE

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Clinical Course in Days	Died
1 ^{6,17,27, 28}	1974	VA	47	F	Black/ Unknown	Diabetes, well water	~21 (s); 7 (h)	Y
2 ^{6,16,78, 79}	1978	SC	.4	M	White/ Unknown	Seizure activity, pneumonia	~35 (s); 5 (h)	Y
3 ^{6,16,79, 80}	1979	PA	2.5	M	Unknown/ Unknown	Unknown	240 (s)	Y
4 ^{6,16,79}	1982	CA	.8	F	Unknown/ Unknown	Unknown	15 (s)	Y
5 ^{6,16}	1983	FL	61	M	Unknown/ Unknown	Alcohol misuse, TB	112 (s)	Y
6 ⁶	1984	CA	72	M	Unknown/ Unknown	Unknown	Unknown	Y
7 ^{6,16,79, 81}	1986	TX	11	F	Unknown/ Hispanic	Healthy, soil exposure	150 (s)	Y
8 ¹⁶	1990	NV	60	M	Unknown/ Unknown	Alcohol misuse	Unknown	Y
9 ⁸²	1990	NC	1.5	M	Unknown/ Unknown	Unknown, water exposure	~23 (h)	Y
10 ⁸³	1991	TX	.11	F	Unknown/ Hispanic	Healthy	~28 (s)	Y
11 ⁸⁴	1991	NV	.6	F	Unknown/ Unknown	Otitis, pharyngitis	~25 (h)	Y
12 ⁷⁹	1992	AZ	13	F	Unknown/ Unknown	Healthy	~16 (s)	Y
13 ⁸⁵	1993	TX	5	M	White/ Unknown	Healthy	~57 (s)	Y
14 ⁷⁹	1993	AZ	2.3	M	Unknown/ Unknown	Otitis	~23 (s)	Y
15 ⁸⁵	1993	TX	15	M	Unknown/ Hispanic	Healthy	~72 (s)	Y
16 ⁸⁶	1995	MD	34	F	Unknown/ Unknown	HIV	~24 (h)	Y
17 ^{87,88}	1996	CA	32	M	Unknown/ Unknown	IVDA,	~42 (s)	Y

					Hispanic	alcohol misuse		
18 ⁸⁹	1996	CO	3	M	Unknown/ Unknown	Pharyngitis	~17 (s)	Y
19 ⁹⁰	1999	MA	52	F	Unknown/ Unknown	Chronic sinus infections, chronic idiopathic neutropenia	~105 (s)	Y
20 ⁹¹	1999	VT	5	F	Unknown/ Unknown	Healthy, water exposure	75 (h)	Y
21 ^{62,88}	2000	CA	5	F	Unknown/ Hispanic	Healthy	~485 (h); multiple hospitalizations	N
22 ^{7,8,63,92,93}	2001	CA	3	F	White/ Hispanic	Otitis	~24 (s)	Y
23 ⁶³	2001	TX	2	M	Unknown/ Hispanic	Unknown	Unknown	Y
24 ^{63,93,94}	2001	CA	7	M	Unknown/ Hispanic	Unknown	~45 (s)	Y
25 ⁹³	2002	CA	64	M	Unknown/ Hispanic	Unknown, occupational soil exposure	~8 (s)	Y
26 ⁹⁵	2002	FL	40	M	Unknown/ Unknown	Alcohol and drug abuse	~10 (h)	Y
27 ⁹⁶	2002	NY	72	F	Unknown/ Unknown	Healthy, soil exposure	~27 (s)	N
28 ^{93,94}	2003	CA	7	M	Unknown/ Hispanic	Steroid therapy	3 (h) from final hospitalization	Y
29 ⁹³	2005	CA	19	M	Unknown/ Hispanic	Former drug abuse	8 (h)	Y
30 ⁹³	2005	CA	12	M	Unknown/ Hispanic	Unknown, soil exposure	120 (h)	Y
31 ⁹³	2007	CA	35	M	Unknown/ Hispanic	Unknown	Unknown	N
32 ⁹⁷	2007	KY	2	M	Unknown/ Unknown	Healthy	~62 (h)	N
33 ^{93,98}	2007	CA	43	M	White/ Unknown	Pneumonia, idiopathic thrombocytopenic purpura, occupational soil exposure	~117 (s)	Y
34 ⁹⁹	2007	Unkn own	Unk now n	Unk now n	Unknown/ Unknown	Multiple visceral organ transplant	Unknown	Y
35 ⁹³	2007	CA	72	M	Pacific Islander/ Unknown	Unknown, gardening	7 (h)	Y

36 ⁹³	2008	CA	1.6	M	Unknown/ Hispanic	Unknown	35 (h)	Y
37 ¹⁸	2009	MS	4	M	Unknown/ Unknown	Influenza A, water & soil exposure	~12 (s)	Y
38 ¹⁸	2009	MS	31	F	Unknown/ Unknown	Kidney transplant	~55 d (s)	Y
39 ¹⁸	2009	MS	27	M	Unknown/ Unknown	Kidney transplant	~139 (s)	N

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).

TB = Tuberculosis; HIV = Human Immunodeficiency Virus; IVDA = intravenous drug abuse

Table 5: Cutaneous acanthamoebiasis

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Clinical Course in Days	Died
1 ^{6,22,39,100}	1989	NY	38	M	Unknown/ Unknown	HIV, pneumonia	>21 (s)	Y
2 ^{22,23,39,44}	1990	IL	60	M	Unknown/ Hispanic	AIDS, PCP	~40 (s)	Y
3 ^{22,39,40}	1991	CA	30	M	Unknown/ Unknown	AIDS, PCP, chronic sinusitis	~77 (s)	Y
4 ^{39,101}	1991	VA	42	M	Unknown/ Unknown	AIDS	42 (s)	Y
5 ^{22,34,102}	1992	NY	31	M	Unknown/ Unknown	ESRD, Kidney transplant, diabetes	~420 (s), con't treatment after lesions resolved	N
6 ^{22,103}	1994	DC	44	M	Unknown/ Unknown	AIDS, progressive myelitis, peripheral neuropathy, water exposure	~450 (s)	Y
7 ^{22,40,104}	1995 ?	CA	38	M	White/ Unknown	AIDS, PCP, chronic sinusitis, water exposure	Unknown	Y
8 ^{22,105}	1996	CA	27	F	Unknown / Hispanic	AIDS	~240 (s)	Y
9 ^{22,106}	1997 ?	MI	44	M	Unknown/ Unknown	AIDS, TB	~180 (s)	Y
10 ^{22,106}	1997 ?	MI	38	M	Unknown/ Unknown	AIDS	~62 (s)	Y
11 ¹⁰⁷	2003	MD	51	F	Unknown/ Unknown	AIDS, PCP	~31 (s)	N
12 ¹⁰⁸	2004	CA	52	F	Unknown/ Unknown	Lung transplant, immune- Suppressants, creek as drinking water source	~150 (h)	N

*Clinical course may mean from symptom onset until death or resolution of illness(s) or from presentation/hospitalization until death or resolution of illness (h).
 AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = *Pneumocystis carinii* pneumonia, ESRD = end-stage renal disease; TB = Tuberculosis

Table 6: *Acanthamoeba* Rhinosinusitis

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Clinical Course in Days	Died
1 ⁵³	1994	Unk	45	M	Unknown/ Unknown	HIV, chronic sinusitis	Unknown	N
2 ¹⁰⁹	2005	FL	49	F	Unknown/ Unknown	Bilateral lung transplant, immuno-suppressants, steroids	Unknown	N

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).
 HIV = Human Immunodeficiency Virus

Table 7: *Acanthamoeba* osteomyelitis

Case (Ref)	Yr	State	Age (yr)	Sex	Race/ Ethnicity	Health Status	Clinical Course in Days	Died
1 ¹¹⁰	1979	PA	32	F	White/ Unknown	Suspected diabetes	Unknown	N

*Clinical course may mean from symptom onset until death or resolution of illness (s) or from presentation/hospitalization until death or resolution of illness (h).

Appendix B: Case Report Form

Date of Report: _____

Demographics

Patient's Last Name _____ First _____ M.I. _____		Age _____	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown
Ethnicity: <input type="checkbox"/> Hispanic <input type="checkbox"/> Unknown <input type="checkbox"/> Non-Hispanic	Race: <input type="checkbox"/> White <input type="checkbox"/> Asian/Pacific Islander <input type="checkbox"/> Unknown <input type="checkbox"/> Black <input type="checkbox"/> American Indian <input type="checkbox"/> Other _____	County and State of Residence: _____ County and State of Treatment: _____	
Immigrant? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown		Country of origin: _____	Occupation: _____
Length of time since immigrated: _____			

Exposure History

County/State of Suspected Exposure: _____ / _____ Number of persons exposed (if known): _____

Source of possible exposure, if known: (please check all that apply and provide best estimates of dates)

Water Exposures <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <i>If "yes", please fill out section on right</i>	Type: <input type="checkbox"/> Canal <input type="checkbox"/> Lake <input type="checkbox"/> Pond <input type="checkbox"/> Ocean <input type="checkbox"/> River/Stream <input type="checkbox"/> Well <input type="checkbox"/> Other, specify _____	Date(s): _____ _____ _____	Type: <input type="checkbox"/> Private Club Pool <input type="checkbox"/> Private Home Pool <input type="checkbox"/> Fill-and-Drain Pool <input type="checkbox"/> Hotel Pool <input type="checkbox"/> Spring (hot/cold) <input type="checkbox"/> Spa/hot tub/whirlpool	Date(s): _____ _____ _____	Type: <input type="checkbox"/> Community Pool <input type="checkbox"/> Apartment Pool <input type="checkbox"/> Fountain <input type="checkbox"/> Water park	Date(s): _____ _____ _____	
Water Activities <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <i>If "yes", please fill out specifics on right</i>	Diving into water Inhaled water Jumped into water Swallowed water Splashed water	Yes No Unknown <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Snorkeling/scuba diving Swimming Water sports (skiing etc.) Wore nose clip or plugged nose when jumping/diving Other, specify _____	Yes No Unknown <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>			
Soil Exposures <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <i>If "yes", please fill out specifics on right</i>	Type: <input type="checkbox"/> Gardening <input type="checkbox"/> Composting <input type="checkbox"/> Farm/Ranch <input type="checkbox"/> Other, specify _____	Date(s): _____ _____ _____		Occupational Exposures <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <i>If "yes", please fill out specifics on right</i>			<input type="checkbox"/> Farmer/rancher <input type="checkbox"/> Firefighter <input type="checkbox"/> Lifeguard/pool attendant <input type="checkbox"/> Other, specify _____

Route of Entry if known: (please check all that apply)
 Inhalation Contact Other, specify: _____
 Ingestion Via Wound

If Water Source, Please List Source Characteristics:

Name of Water Exposure: _____ Geospatial Coordinates: _____ Thermally Polluted: Y / N
 Size of Body Water: < 10 acres 10-100 acres >100 acres Unknown
 Water Turbidity: Clear Cloudy Murky Unknown
 Water level: Low High Normal Flood Stage Unknown
 Ambient Air Temperature: ___ F/C Water Temperature: ___ F/C Depth: _____
 Flow Rate: Slow Normal Fast Unknown

Travel History last 2 years: Yes No Unknown If yes, please specify in table below:

Locations	Dates (from – to)

Past Medical History:

Please check all conditions/symptoms that patient has currently or has had within past 2 years:

Treatment/drugs:

- Excessive antibiotic use (specify in Provider comments)
- Illegal drug use, specify: _____
- Immunosuppressants
- Radiation therapy
- Steroid use

HIV/AIDS:

HIV	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Unknown
AIDS	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Unknown
On Antiretrovirals	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Unknown

Other Immunocompromised Conditions

- Alcohol misuse Diabetes mellitus
- G6PD deficiency Liver cirrhosis
- Malnourishment Pregnancy (recent)
- Renal failure Lymphoproliferative disease
- Systemic Lupus Erythematosus (SLE)
- Cancer, specify: _____
- Other hematologic disease, specify: _____
- Other autoimmune disease, specify: _____
- Organ transplant, specify: _____

ENT/Respiratory:

- Otitis
- Rhinitis
- Broken Nose
- Deviated septum
- Tuberculosis
- Other lung disease, specify: _____

- Sinusitis
- Epistaxis
- Nasal Surgery
- Pharyngitis
- Pneumonitis

Other Conditions:

- Dermatitis
- Skin infections
- Eye infection
- Other, specify: _____
- Injury, specify: _____

Current Illness

Date of Illness onset: _____

Duration of illness: (in days) _____

Was patient admitted to hospital for current illness? Yes No Unknown

If Yes, Date of **most recent** hospitalization: _____ Duration of most recent hospitalization (in days): _____

Hospital Name: _____ City: _____ State: _____

Physician Name 1: _____ E-mail (if avail): _____ Phone: _____

Physician Name 2: _____ E-mail (if avail): _____ Phone: _____

Other Recent Hospitalizations: Yes No Unknown

Dates (from- to)	Diagnosis

History of Present Illness:

Please provide a brief description of the patient's clinical course, prior to hospitalization:

Signs/Symptoms on Presentation (most recent hospitalization):**Vital****Signs:**

Temperature: _____ F / C P: _____ bpm R= _____ breaths/min BP: _____ mmHg

General:

	Duration (days)		Duration (days)
<input type="checkbox"/> Fever	_____	<input type="checkbox"/> Myalgia	_____
<input type="checkbox"/> Nausea	_____	<input type="checkbox"/> Back Pain	_____
<input type="checkbox"/> Vomiting	_____	<input type="checkbox"/> Cough	_____
<input type="checkbox"/> Diarrhea	_____	<input type="checkbox"/> Shortness of breath	_____
<input type="checkbox"/> Weight loss	_____	<input type="checkbox"/> Sinus problems	_____
<input type="checkbox"/> Anorexia	_____	<input type="checkbox"/> Abnormal reflexes	_____
<input type="checkbox"/> Headache	_____	<input type="checkbox"/> Disorientation	_____
<input type="checkbox"/> Stiff neck	_____	<input type="checkbox"/> Lethargy/fatigue	_____
<input type="checkbox"/> Other general symptom/sign, specify: _____			_____

Visual

	Duration (days)
<input type="checkbox"/> Blurred vision	_____
<input type="checkbox"/> Diplopia	_____
<input type="checkbox"/> Photophobia	_____
<input type="checkbox"/> Other visual changes, specify: _____	_____

Neurologic:

	Duration (days)		Duration (days)		Duration (days)
<input type="checkbox"/> Altered mental status	_____	<input type="checkbox"/> Dysphagia	_____	<input type="checkbox"/> Weakness	_____
<input type="checkbox"/> Aphasia	_____	<input type="checkbox"/> Facial numbness/Parathesia	_____	<input type="checkbox"/> Hemiparesis/Hemiplegia	_____
<input type="checkbox"/> Ataxia	_____	<input type="checkbox"/> Hallucinations	_____	<input type="checkbox"/> Altered sense of taste	_____
<input type="checkbox"/> Behavioral changes	_____	<input type="checkbox"/> Combativeness	_____	<input type="checkbox"/> Altered sense of smell	_____
<input type="checkbox"/> Coma	_____	<input type="checkbox"/> Hyperreflexia	_____	<input type="checkbox"/> Decerebrate posturing	_____
<input type="checkbox"/> Confusion	_____	<input type="checkbox"/> Loss of balance	_____	<input type="checkbox"/> Decorticate posturing	_____
<input type="checkbox"/> Cranial nerve VI deficit	_____	<input type="checkbox"/> Numbness	_____	<input type="checkbox"/> Fixed, nonreactive pupils	_____
<input type="checkbox"/> Cranial nerve VII deficit	_____	<input type="checkbox"/> Seizures	_____	<input type="checkbox"/> Dilated pupils	_____
<input type="checkbox"/> Cranial nerve XII deficit	_____	<input type="checkbox"/> Upgoing toes	_____	<input type="checkbox"/> Nystagmus	_____
<input type="checkbox"/> Other cranial nerve deficit, specify: _____	Duration: _____	<input type="checkbox"/> Other neurologic deficit, specify: _____	Duration: _____		

Skin Lesions: Yes No Unknown *If yes, please specify in table below.*

Lesion type	Anatomic location	Size	Number	Duration (days)
Ulcers				
Plaques				
Erythematous nodules				
Other				

Other Symptoms/Signs:

Other, specify: _____

Signs/Symptoms developed while in hospital:**General:**

- Fever
 Nausea
 Vomiting
 Diarrhea
 Weight loss
 Anorexia
 Headache
 Stiff neck
 Other general symptom/sign, specify: _____
- Myalgia
 Back Pain
 Cough
 Shortness of breath
 Sinus problems
 Abnormal Reflexes
 Disorientation
 Lethargy/fatigue

Visual

- Blurred vision
 Diplopia
 Photophobia
 Other visual changes, specify: _____

- Altered mental status
 Aphasia
 Ataxia
 Behavioral changes
 Coma
 Combativeness
 Confusion
 Cranial nerve VI deficit
 Cranial nerve VII deficit
 Cranial nerve XII deficit
 Other Cranial nerve deficit, specify: _____
- Dysphagia
 Facial numbness/Parathesia
 Hallucinations
 Hemiparesis/Hemiplegia
 Hyperreflexia
 Loss of balance
 Numbness
 Seizures
 Upgoing toes
 Weakness
 Other neurologic deficit, specify: _____
- Altered sense of taste
 Altered sense of smell
 Decerebrate posturing
 Decorticate posturing
 Fixed, nonreactive pupils
 Dilated pupils
 Nystagmus

Neurologic:

Skin Lesions: Yes No *If yes, please specify in table below:*

Lesion type	Anatomic location	Size	Number
Ulcers			
Plaques			
Erythematous nodules			
Other			

Other Symptoms/Signs:

Other, specify: _____

Diagnostic Tests: Note please provide dates when possible. If date not available, provide hospital day (i.e. CSF tap on Hosp. Day 2)

LABORATORY TESTING

CSF	Date _____	Date _____	Date _____
	Results	Results	Results
Opening pressure (mmH2O)			
WBC count (per mm ³)			
RBC count (per mm ³)			
Neutrophil %			
Monocyte %			
Lymphocyte %			
Bands %			
Eosinophil %			
Protein (mg/100ml)			
Glucose (mg/100ml)			
Cytokines			
CSF Culture: *			
CSF PCR: *			
CSF latex agglutination: *			
CSF mount: <i>Please indicate preparation type and findings, if any</i>	<input type="checkbox"/> Centrifuged <input type="checkbox"/> Stained <input type="checkbox"/> Wet Amoebae present? Y <input type="checkbox"/> N <input type="checkbox"/>	<input type="checkbox"/> Centrifuged <input type="checkbox"/> Stained <input type="checkbox"/> Wet Amoebae present? Y <input type="checkbox"/> N <input type="checkbox"/>	<input type="checkbox"/> Centrifuged <input type="checkbox"/> Stained <input type="checkbox"/> Wet Amoebae present? Y <input type="checkbox"/> N <input type="checkbox"/>

* Please provide results for all bacteria, viral and/or parasitic testing.

Presenting Lab Values: Date: _____

	Results
RBC count (per mm ³)	
Hematocrit %	
WBC count (per mm ³)	
Neutrophil %	
Lymphocyte %	
Monocyte %	
Eosinophil %	
Bands %	
CD4 count (per mm ³)	
Protein (mg/100ml)	
Sodium (mEq/L)	
Potassium (mEq/L)	
Chloride (mEq/L)	
Bicarbonate (mEq/L)	
BUN (mg/100ml)	
Creatinine (mg/100ml)	
Glucose (mg/100ml)	

Serology:

Date	Result

Cultures for Free Living Amebae:

Source	Date	Result	
<input type="checkbox"/> Blood		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Skin		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Brain		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Abscess		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Other, specify: _____		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba

PCR for Free Living Amebae:

Source	Date	Result	
<input type="checkbox"/> Blood		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Skin		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Brain		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Abscess		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba
<input type="checkbox"/> Other, specify: _____		<input type="checkbox"/> Negative	<input type="checkbox"/> + Balamuthia
		<input type="checkbox"/> + Naegleria	<input type="checkbox"/> + Acanthamoeba

HISTOPATHOLOGY**Brain biopsy:** Yes No Unknown

	Date:	Date:
Location		
Timing	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown
Results (check all that apply)	<input type="checkbox"/> Amebic trophozoites	<input type="checkbox"/> Amebic trophozoites
	<input type="checkbox"/> Amebic cysts	<input type="checkbox"/> Amebic cysts
	<input type="checkbox"/> Ameba, not specified	<input type="checkbox"/> Ameba, not specified
	<input type="checkbox"/> Hemorrhage	<input type="checkbox"/> Necrosis
	<input type="checkbox"/> Encephalomalacia	<input type="checkbox"/> Edema
	<input type="checkbox"/> Abscess	<input type="checkbox"/> Vasculitis
	<input type="checkbox"/> Perivascular Inflammation	<input type="checkbox"/> Perivascular Inflammation
	<input type="checkbox"/> Thrombosis	<input type="checkbox"/> Thrombosis
	<input type="checkbox"/> Neovascularization	<input type="checkbox"/> Neovascularization
	<input type="checkbox"/> Neutrophilic inflammation / infiltrate	<input type="checkbox"/> Neutrophilic inflammation / infiltrate
	<input type="checkbox"/> Lymphocytic inflammation / infiltrate	<input type="checkbox"/> Lymphocytic inflammation / infiltrate
	<input type="checkbox"/> Granulomatous inflammation	<input type="checkbox"/> Granulomatous inflammation
	<input type="checkbox"/> Granuloma	<input type="checkbox"/> Granuloma
	<input type="checkbox"/> Meningitis	<input type="checkbox"/> Encephalitis
<input type="checkbox"/> Meningoencephalitis	<input type="checkbox"/> Meningoencephalitis	
Other Results/ Comments		

Skin biopsy: Yes No Unknown

	Date:	Date:
Location		
Timing	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown
Results	<input type="checkbox"/> No amebae seen <input type="checkbox"/> Amebic trophozoites <input type="checkbox"/> Amebic cysts <input type="checkbox"/> Amebae, not specified	<input type="checkbox"/> No amebae seen <input type="checkbox"/> Amebic trophozoites <input type="checkbox"/> Amebic cysts <input type="checkbox"/> Amebae, not specified
Other Results/ Comments		

Sinus biopsy: Yes No Unknown

	Date:	Date:
Location		
Timing	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown	<input type="checkbox"/> Antemortem <input type="checkbox"/> Postmortem <input type="checkbox"/> Unknown
Results	<input type="checkbox"/> No amebae seen <input type="checkbox"/> Amebic trophozoites <input type="checkbox"/> Amebic cysts <input type="checkbox"/> Amebae, not specified	<input type="checkbox"/> No amebae seen <input type="checkbox"/> Amebic trophozoites <input type="checkbox"/> Amebic cysts <input type="checkbox"/> Amebae, not specified
Other Results/ Comments		

Other biopsy results:

DIAGNOSTIC IMAGING

CT: Date of First CT: _____

Lesion location: (please check all that apply)

- | | | |
|---|--|--|
| <input type="checkbox"/> Basal Ganglia | <input type="checkbox"/> Left Occipital | <input type="checkbox"/> Left Temporal |
| <input type="checkbox"/> Brainstem | <input type="checkbox"/> Right Occipital | <input type="checkbox"/> Right Temporal |
| <input type="checkbox"/> Right Cerebellum | <input type="checkbox"/> Left Parietal | <input type="checkbox"/> Thalamus |
| <input type="checkbox"/> Left Cerebellum | <input type="checkbox"/> Right Parietal | <input type="checkbox"/> Other, specify: _____ |
| <input type="checkbox"/> Left Frontal | <input type="checkbox"/> Pons | |
| <input type="checkbox"/> Right Frontal | <input type="checkbox"/> Spinal Cord | |

Lesion: (please check all that apply)

- | | | | |
|-------------------------------------|---|--|---|
| <input type="checkbox"/> Abscess | <input type="checkbox"/> Hyperdense | <input type="checkbox"/> Enhancing | Additional
Description,
if
needed: |
| <input type="checkbox"/> Edema | <input type="checkbox"/> Hypodense | <input type="checkbox"/> Ring enhancing | |
| <input type="checkbox"/> Erosion | <input type="checkbox"/> Infarcts | <input type="checkbox"/> Sinusitis | |
| <input type="checkbox"/> Hemorrhage | <input type="checkbox"/> Mass | <input type="checkbox"/> Ventriculomegaly | |
| <input type="checkbox"/> Herniation | <input type="checkbox"/> Multifocal lesions | <input type="checkbox"/> Other, specify: _____ | |
| | | | |

Please list dates of subsequent CT scans and changes noted:

Date	Findings

MRI: Date of First MRI: _____

Lesion location: (please check all that apply)

- | | | |
|---|--|--|
| <input type="checkbox"/> Basal Ganglia | <input type="checkbox"/> Left Occipital | <input type="checkbox"/> Left Temporal |
| <input type="checkbox"/> Brainstem | <input type="checkbox"/> Right Occipital | <input type="checkbox"/> Right Temporal |
| <input type="checkbox"/> Right Cerebellum | <input type="checkbox"/> Left Parietal | <input type="checkbox"/> Thalamus |
| <input type="checkbox"/> Left Cerebellum | <input type="checkbox"/> Right Parietal | <input type="checkbox"/> Other, specify: _____ |
| <input type="checkbox"/> Left Frontal | <input type="checkbox"/> Pons | |
| <input type="checkbox"/> Right Frontal | <input type="checkbox"/> Spinal Cord | |

Lesion: (please check all that apply)

- | | | | |
|-------------------------------------|---|--|---|
| <input type="checkbox"/> Abscess | <input type="checkbox"/> Hyperdense | <input type="checkbox"/> Enhancing | Additional
Description,
if
needed: |
| <input type="checkbox"/> Edema | <input type="checkbox"/> Hypodense | <input type="checkbox"/> Ring enhancing | |
| <input type="checkbox"/> Erosion | <input type="checkbox"/> Infarcts | <input type="checkbox"/> Sinusitis | |
| <input type="checkbox"/> Hemorrhage | <input type="checkbox"/> Mass | <input type="checkbox"/> Ventriculomegaly | |
| <input type="checkbox"/> Herniation | <input type="checkbox"/> Multifocal lesions | <input type="checkbox"/> Other, specify: _____ | |
| | | | |

Please list dates of subsequent MRI scans and changes noted:

Date	Findings

Other therapies: (please check all that apply)

	Start date:	Stop date:
<input type="checkbox"/> IV fluids		
<input type="checkbox"/> Total Parenteral Nutrition (TPN)		
<input type="checkbox"/> Dialysis for renal failure		
<input type="checkbox"/> Other, specify _____		
<input type="checkbox"/> Other, specify _____		
<input type="checkbox"/> Other, specify _____		

Outcome:Survived? Yes No Unknown If survived: Residual neurologic deficits? Yes No Unknown

If Yes, Please describe neurologic deficits: _____

Date of discharge: _____ OR Date of death: _____

If died: Cause of death:

- Brain death Removed life support
 Cardiorespiratory failure Other, specify: _____
 Herniation

If died: Organs Yes No transplanted?

If yes, which ones: _____

Please provide a brief description of the patient's clinical course, complications, and any additional comments:

CDC USE ONLY:

1 st DASH #	
2 nd DASH #	
3 rd DASH #	
4 th DASH #	
5 th DASH #	
List additional DASH #s:	

Case report citation 1	
Case report citation 2	
List additional case citations	

Calculated durations:

Incubation period (days): _____


Illness Onset to Admission (days): _____

Illness Onset to Death (days): _____


Exposure to Death (days): _____

Clinical Stage at presentation: _____

Epidemic Curve by Age for *Acanthamoeba* spp. Cases




Epidemic Curve by Age for *Balamuthia mandrillaris* Cases



Appendix D: Treatment Regimens for Survivors

Case 17 - Disseminated acanthamoebiasis (skin and osteomyelitis)




Case 23 - Disseminated acanthamoebiasis (skin, BAL, liver)




Case 24 - Disseminated acanthamoebiasis (skin and sinus)




Case 6 - Cutaneous acanthamoebiasis



Case 11 - Cutaneous acanthamoebiasis




Case 12 - Cutaneous acanthamoebiasis




Survivors of disseminated acanthamoebiasis

Survivors of cutaneous acanthamoebiasis



Survivor of disseminated balamuthiasis



Survivors of *Balamuthia* GAE

